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Abstract 
 
Background: Functioning is impaired in individuals at ultra-high-risk (UHR) for 
schizophrenia. Social cognition is a significant predictor of functioning in those with 
schizophrenia, and while social cognition is impaired in UHR individuals it is unclear 
whether social cognitive deficits are associated with poor functioning in the UHR 
population. Understanding this could improve early intervention efforts.  
Methods: Psycinfo, Medline and CINAHL databases were searched on 14th May 2019 
using keywords related to ultra-high risk, schizophrenia, functioning and social 
cognition. Eligible studies examined an association between functioning and social 
cognition in UHR participants. 
Results: Eleven eligible studies were identified, with overlapping samples in six of 
these. Methodological quality was average to good. Emotion recognition and Theory of 
Mind were the most studied domains. Better and faster recognition of negative 
emotions was associated with better functioning with small to moderate effect sizes. 
There was limited evidence theory of mind was associated with functioning, but this 
may reflect differences in IQ or cognition. Findings regarding attribution bias were 
mixed and interpretation was limited by poor quality measurement.  
Conclusions: Social cognition deficits, in particular emotion recognition appear to be 
associated with poor functioning in UHR individuals but there remains a relatively 
small number of studies in this area with varying methodological quality. Further 
research with independent samples and longitudinal designs and consideration of key 
mediator and moderator variables can extend these findings.  
 
Keywords:  psychosis; emotion recognition; functioning; at-risk mental state  
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Introduction 
 
Social cognitive deficits are a key determinant of functioning in schizophrenia and are 
thought to be impaired prior to the onset of active psychosis. It is not understood how 
this is associated with functioning in individuals at high-risk of developing 
schizophrenia. Improving our understanding of this relationship is crucial for 
improving early intervention efforts and enhancing our understanding of how social 
cognitive deficits contribute to illness development and progression.   
 
Social Cognition in Schizophrenia 
 
The term social cognition describes cognitive processes facilitating flexible social 
behaviour such as detecting intentions and emotions in others and knowledge of social 
rules (Adolphs, 1999). It comprises of a number of inter-related but independent 
domains of processing and an expert panel identified four domains thought relevant in 
schizophrenia, alongside recommended measures of each (Pinkham et al., 2015).  
 
• Emotion Recognition (ER) - identify and discriminate expression of emotions 
• Theory of Mind (ToM) – interpret and represent the mental states of others 
• Social Perception (SP) – interpreting social cues including social knowledge of 
rules.  
• Attribution Bias (AB) – how someone makes sense, or explains causes, of 
social events.   
 
Social cognitive deficits in schizophrenia have been well established with meta-
analyses finding large effect sizes for impairments in ToM, SP and ER abilities (Savla 
et al., 2012). These deficits remain stable throughout the illness, being present in both 
first episode and remitted patients (Mehta et al., 2013, Healey et al., 2016) and are 
thought to represent a trait rather than a state dependent deficit. 
 
Individual differences in social cognitive ability is an important determinant of 
psychosocial functioning - broadly defined as the extent to which an individual 
performs different social roles including work, interpersonal relationships, activities of 
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daily living and recreation, as well as their functional capacity and subjective wellbeing 
or quality of life (Priebe, 2007). Functioning is an important target for recovery given 
the long-term disability associated with schizophrenia which is not consistently 
alleviated by pharmacological interventions (Brissos et al., 2011). Social cognitive 
ability accounts for a quarter of variance in functional outcomes in schizophrenia, and 
this has been shown to be partially independent of non-social cognitive processes such 
as memory and attention (Fett et al., 2011). As a result, interventions have been 
developed to remediate or recover social cognitive ability to improve functioning. 
These interventions have been shown to improve underlying social cognitive abilities, 
such as the ability to correctly identify emotions, but less consistently improve 
psychosocial functioning (Tan et al., 2018).  
 
Ultra-High-Risk Concept 
 
Intervening during a prodromal phase of schizophrenia may improve outcomes, with 
length of untreated illness thought to significantly contribute to poorer outcomes 
(Fusar-Poli et al., 2009, Keshavan et al., 2003). This necessitates detecting individuals 
prior to onset, which has led to development of criteria and screening tools to identify 
those at ultra-high risk (UHR; See table 1) (Yung et al., 2005, Miller et al., 2002, 
Schultze-Lutter et al., 2007). However, these criteria identify a relative heterogenous 
group, with only 22-36% converting to psychosis within three years (Fusar-Poli et al., 
2012). 
 
Social Cognition and Functioning in UHR  
  
Both social cognition and functioning are impaired in UHR individuals, regardless of 
later transition to schizophrenia (van Donkersgoed et al., 2015, Lee et al., 2015). Two 
meta-analyses examining social cognitive deficits in UHR individuals found moderate 
effect sizes for impaired ER and ToM with the evidence for AB being more equivocal 
due to a lack of research and inconsistencies in the definition of AB. 
 
It is important to determine whether social cognitive abilities are related to 
psychosocial functioning prior to onset of psychosis. Firstly, given the promise of 
social cognition interventions for improving functioning in individuals with 
schizophrenia, understanding how these factors interact in the UHR state may provide 
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indications for prodromal phase interventions to improve functioning. Secondly, the 
neurodevelopmental model posits that schizophrenia is the end result of a series of 
biological and environmental risk factors leading to impaired cognition and functioning 
which result in illness (Murray and Lewis, 1987, Murray et al., 2017), and poor 
premorbid functioning is predictive of illness onset and outcome (Cannon-Spoor et al., 
1982). Understanding the relationship between social cognition and functioning prior to 
illness onset will improve our understanding of how social processing abilities might 
contribute to psychosis development and outcomes.  
 
 
 
 
A systematic review of 72 studies examining factors associated with poor functioning 
in the UHR group concluded that neurocognitive deficits and negative and disorganised 
symptoms predicted functional outcomes (Cotter et al., 2014). Only three of the 
included studies examined the association between social cognition and functioning 
with mixed support for an association. Initial searches of the literature indicated that 
since 2014, there has been a significant increase in research looking at social cognition 
Table 1: UHR Criteria  
Subgroup Criteria 
Attenuated Psychotic 
Symptoms (APS)   
Subthreshold, positive APS during the 
past year. 
Brief limited intermittent 
psychotic symptom (BLIPS)  
Episodes of frank psychotic symptoms 
not lasting longer than a week which 
spontaneously abated without treatment 
Trait and State Risk Factor  
First-degree relative with a psychotic 
disorder or schizotypal personality 
disorder (SPD) and significant decrease 
in functioning or chronic low functioning 
during the previous year. 
Basic Symptoms 
Subjective abnormalities in the realms of 
cognition, attention, perception, and 
movement. 
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and functioning. Given the lack of conclusions which could be drawn from the previous 
review and a significant body of further literature this area warrants further review.   
 
Aims 
 
The aim of the current review is to summarise the research that examines the 
relationship between social cognition and functioning in individuals who meet ultra-
high-risk criteria for developing schizophrenia.  
 
 
Method 
 
This review was conducted in line with Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement guidelines (Moher et al., 2009). A 
Prospero search revealed no similar ongoing reviews.  
 
Search Strategy  
 
On 14th May 2019 an electronic database search was performed on: Psycinfo (EBSCO), 
CINAHL (EBSCO) and Medline (Ovid). Keywords and subject headings related to 
schizophrenia, UHR, functioning and social cognition were combined and adapted 
according to database. See Appendix 1.2 for full search strategy. No limiters were 
applied.  
 
Duplicates were removed and title and abstracts screened. Full texts of papers not 
clearly excluded were examined to determine eligibility. To identify articles not 
returned by the electronic search, the journal Schizophrenia Research and the reference 
list of eligible studies were hand-searched.  
 
Eligibility Criteria  
 
Included papers reported original research published in peer reviewed journals which 
examined an association between functioning and social cognition in individuals who 
met criteria for UHR based on a validated screening tool. For the purpose of this 
review, relevant domains of social cognition are those identified in the SCOPE review 
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(Pinkham et al., 2013): (1) ToM (2) ER (3) SP (4) AB. Functional outcome was defined 
on the basis of previous reviews – community functioning, social behaviour in the 
milieu, social problem solving and social skills (Green et al., 2000, Couture et al., 
2006). 
 
Studies which defined “risk” solely as familial or genetic risk or where UHR 
participants were not reported independently were excluded. Book chapters, 
dissertations, systematic reviews or meta-analyses, study protocols, poster abstracts, 
conference proceedings and studies published in a language other than English were 
excluded.  
 
 
Data Extraction and Synthesis 
 
A data extraction form was developed to collate study data (see Appendix 1.3). Due to 
the variability in the measurement of functioning and social cognition, a narrative 
synthesis approach was used. Results are described according to the domain of social 
cognition examined due to the finding from previous research that different social 
cognitive domains are differentially associated with functioning (Couture et al., 2006). 
Correlation coefficients will be used to describe the estimated effect size of the 
association between social cognition and functioning. For regression analysis, r will be 
calculated from the relevant t statistic using the following equation:  √ t2 / (t2 + DF)  
and the following cut off conventions used: 0.1 (small), 0.3 (medium) and 0.5 (large) 
(Cohen, 1992). 
 
Quality Assessment 
 
The Crowe Critical Appraisal Tool v1.04 (CCAT; Crowe and Sheppard, 2011) was 
used to assess methodological quality. Eight domains consisting of 22 quality items are 
rated on a 5-point scale depending on the evidence presented. Total scores are 
converted to a percentage to allow comparison across studies. Total scores should be 
interpreted with caution as domains are not equivalent in their importance. An 
independent researcher co-rated 50% of included studies. Discussion was had to 
resolve discrepancies and reach consensus. See Appendix 1.4 for quality ratings for 
domains and overall percentage rating.  
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Results  
 
Following the removal of duplicates, 175 articles were screened. 124 articles were 
excluded from title and abstracts, with full text of the remaining 51 articles screened 
against inclusion criteria. 41 articles were excluded and two further papers identified 
from reference lists leading 12 papers meeting all inclusion criteria.  
 
Papers were then examined for overlapping samples. Von Elm et al.’s (2004) guidance 
on types of sample overlap in published research was used to identify the type of 
overlap present in the papers and to guide decisions on inclusion or exclusion of papers. 
Of the 12 initially identified articles, eight papers were found to have samples derived 
from four cohorts.  
 
Two papers (Thomson et al. 2011 and Cotter et al. 2017) fit pattern 1 of the 
classification and were found to have identical study samples. In addition to this, the 
outcomes reported in the Thomson et al. paper were re-reported in the Cotter et al. 
paper alongside additional outcomes. As such, the Thomson et al. paper was excluded 
from the review, with all findings from it being discussed under the Cotter et al. paper.  
 
Six further papers were identified as fitting pattern four of Von Elm’s classification – 
non-identical samples and non-identical study outcomes. As such, all six studies were 
included in the review and their results are discussed independently. See Table 2 for an 
overview of the cohorts and papers with overlapping samples. See Figure 1 for Prisma 
flowchart of paper identification.  
 
For the purpose of demographic calculations, for papers with overlapping samples, the 
cohort sample size will be used to calculate number of UHR participants included in 
the review. For papers with overlapping samples, the cohort mean ages will be 
extracted from the paper with the largest sample size.   
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Table 2 Summary of Sample Cohorts 
Cohort  Cohort N and 
description 
Papers  Paper 
N 
Description 
of Sample 
overlap   
Description of outcome overlaps Included 
or 
Excluded?  
Cotter 
N = 30  
Subsample of 
larger study 
Thomson et al. 
2013 
30 Samples in these 
two papers 
overlap 
completely 
Stanford et al. report on AB and functioning. 
Cotter et al. report on AB, ToM, ER and SP and 
re-report Stanford et al. results.  
Excluded 
Cotter et al. 
2013 
30 Included 
Amminger 
N= 79  
Total sample 
recruited for RCT 
Amminger et 
al. 2013 
79 Bartholomeusz 
et al. report on 
sub-sample of 
overall cohort  
Bartholomeusz et al. report on MRI findings not 
reported in Amminger et al.  
Included 
Bartholomeusz 
et al. 2014 
39 Included 
Stanford N= 63 
Sample recruited 
for longitudinal 
study  
Standford et al. 
2011 
63 DeVylder et al. 
report on 
subsection of 
overall cohort.  
Stanford et al. report on ToM and Functioning 
outcomes while DeVylder et al. report on AB 
and functioning 
Included 
DeVylder et al. 
2013 
33 Included 
Glenthoj  N=146  Glenthoj et al. 
2016 
65 Glenthoj et al. 
2016 report on 
Included 
13 
 
Total sample 
recruited for RCT 
Glenthoj et 
al. 2018 
146 data collected 
between 2014-
2016 while 
Glenthoj et al. 
2018 report on 
the complete 
cohort.  
Glenthoj et al. 2016 report on Theory of Mind, 
Emotion Recognition accuracy and Attribution 
Bias.  
Glenthoj et al. 2018 report on emotion 
recognition latency. 
Included  
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Figure 1: Prisma Flowchart 
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Study Characteristics 
 
Included cohorts reported on 642 (334 female) individual UHR participants with mean 
ages from 16.45-24.59. Four papers included a control group. All papers reported 
cross-sectional data, with 8 papers reporting baseline data from a randomised control 
trial or longitudinal study, while two studies reported data from a sample drawn from a 
larger study. See table 3 for an overview of study characteristics and key findings.  
 
Study Quality  
 
The percentage CCAT ratings ranged from 65-95% with a mean percentage of 72.2, 
indicating studies were of average to good quality with some very high quality. 
Common limitations were inadequate description of sample recruitment (N = 6), 
overlapping samples (N=8), inadequate description of the administration of functioning 
measurements e.g. who provided ratings (N= 6) and publication of baseline data from 
RCT or longitudinal study without description of sample selection (N= 8). Two studies 
used self-report measures of functioning, which have been shown to lack reliability 
(Harvey, 2013) and four studies used the GAF as their only objective rating of 
functioning which has been criticised for conflating symptoms with functioning.   
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Table 3- Study Characteristics and Main Findings 
Cohort Paper 
Sample 
N 
(Male) 
 
 
Mean 
Age 
Other 
Control 
group 
Study 
Type 
FO 
SC 
Domain 
SC 
Measure 
Main Findings 
Cotter Cotter (2017) 30 (14) 19.1 - 
Cross 
sectional 
data from a 
larger study  
GFS-S, 
GFS-R 
SOFAS 
ER 
DANVA-
2 
No correlation between facial or 
prosodic ER and GF-R, GF-S and 
OSFAS.  
ToM 
Hinting 
Task, 
Visual 
Jokes 
ToM correlated with global functioning 
(SOFAS; r=0.54) and role functioning 
(GF-R; r= 0.42). 
ToM predicted global functioning after 
controlling for negative symptoms and 
depression (SOFAS; r = 0.47) but no 
longer predicted GF-R after controlling 
for negative symptoms. 
AB ANSIE No correlation between AB (ANSIE) 
and global, social and role functioning 
SP MSCEIT Trend level association between SP 
(MSCEIT) and global functioning 
(SOFAS; r= 0.36, p=0.051). No 
correlation between SP and role or 
social functioning.   
Amminger 
Amminger 
(2013) 
79 
(26) 
16.5 - 
Baselin
e data 
GAF ER FELT, AP 
Facial emotion recognition not 
correlated with GAF 
17 
 
from 
RCT 
Prosody correlated with GAF (r=0.25) 
after controlling for SANS and MADRS 
Model including AP and symptoms 
accounted for 65% of variance with AP 
contributing 3% unique variance 
Amminger 
Bartholomeusz 
(2014) 
39 
(14)  
16.4
5  
- 
Baselin
e data 
from 
RCT 
GAF ER FELT, AP 
Larger left amygdala volume mediated 
better sadness recognition and worse 
GAF in females  
Amygdala volume mediated better 
sadness recognition and worse 
depression, negative and positive 
symptoms.  
Stanford Stanford (2011) 
63 
(50) 
 
 
19.6 
HC 
Youth 
N=24 
SCZ 
N=13 
HC 
Adult 
N=14 
Baselin
e data 
from 
longitu
dinal 
study 
SAS-
SR 
ToM 
RME 
FBT 
Strange 
Stories 
ToM performance similar to age 
matched controls, better than 
schizophrenia control group and worse 
than older control group.   
ToM performance correlated to IQ and 
group differences in performance no 
longer significant after controlling for 
IQ 
ToM not related to self-reported social 
functioning (SAS-SR) 
Stanford DeVylder (2013) 
33 
(27) 
 
18.7  
HC 
N=15 
Baselin
e data 
from 
longitu
GAF AB IPSAQ 
No correlation between AB (IPSAQ) 
and modified global functioning 
(mGAF) 
No difference in AB between UHR and 
HC 
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dinal 
study  
Glenthoj Glenthoj (2016) 
65 
(26) 
24.5
9  
HC 
N=30 
Baselin
e data 
from 
RCT  
GF-S, GF-
R, SOFAS, 
PSP, 
AQoL18, 
HiSoC, 
SRS-A 
ER 
CANTAB
-ER 
Facial Disgust accuracy negatively 
correlated with GF-R after controlling 
for negative symptoms (r=0.36). 
Disgust and negative symptoms 
together predicted 35.7% of variance in 
GF-R 
Facial Sadness accuracy negatively 
correlated with AQoL after controlling 
for negative and positive symptoms (r = 
0.25). Sadness and symptoms together 
accounted for 23.1% of variance in 
AQoL  
Facial Anger accuracy correlated with 
HiSoC (r=0.31), and sadness accuracy 
correlated with HiSoC (r=0.27) after 
controlling for anger. Together 
predicted 22.4% of HiSoC variance. 
UHR had worse emotion recognition 
than HC. 
Glenthoj Glenthoj 2018 
146 
(66) 
24 - 
Baselin
e data 
from 
RCT 
GF-S, GF-
R 
SOFAS, 
PSP, 
AQoL18 
ER 
CANTAB 
-ER 
Overall latency of correct facial ER 
associated with PSP (r= 0.22), SOFAS 
(r=0.18) and GF-S (r=0.18) 
After controlling for cognitive 
processing speed, only PSP associated 
with overall latency (r=018) 
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PSP associated with sadness (r=0.25) 
and anger (r=0.19) latency 
SOFAS associated with sadness latency 
(r=0.18) 
GF-S associated with happy (r=0.19), 
disgust (r=0.18) surprise (r=0.17) and 
sad (r=0.2) latency 
AQoL associated with sadness latency 
(r=0.17) 
Accuracy was not associated with any 
measure of functioning 
 
Barbato (2013)  
 
137 
(81) 
19.9
6  
- 
Baselin
e data 
from 
longitu
dinal 
study 
SFS 
ER 
FEIT, 
FEDT, 
AP 
FEIT significantly correlated with SFS 
(r = 0.25) 
AP and FEDT did not correlate with 
SFS 
 
ToM 
 
RME 
ToM correlated with self-report social 
functioning (SFS; r=0.18) 
ToM correlated with composite 
cognitive factor score (r=0.63) 
 Clayson (2019)  
43 (31) 
 
18.8 - 
Cross 
section
al study 
GF-S, GF-
R 
 
ER FEIT 
No correlation between pre/ post FEIT 
score, gain scores and functioning.  
Significant correlation between learner 
categorical classification and GF-R 
(Kendall’s Tau B = 0.26) 
 Haining (2019)  108 (26) 
21.8
5  
CHR Neg   
N = 42 
HC N= 55 
Baselin
e data 
from 
GF-S, GF-
R 
ER 
Penn 
CNB ER 
Facial emotion recognition and latency 
together predicted 11% of variance in 
role functioning (r=0.33) 
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Longitu
dinal 
study  
Fear latency predicted 4% of variance 
in GAF scores (r = 0.2) and 10% of 
variance in GF-S (r= 0.31). Fear and 
anger together predicted 12% of 
variance in GF-R (r=0.35). 
Cognitive processing speed predicted 
5% of variance in GF-R (r=0.22)  
UHR participants had worse emotion 
recognition response time but not 
accuracy than HC. 
 Ohmuro (2016) 
36 
(14) 
 
 
20.9 
FEP 
N=40 
HC 
N=25 
Cross 
section
al 
GAF, 
SFS 
ToM 
Picture 
Stories 
Task 
ToM did not correlate with global 
functioning (GAF) or self -reported 
social functioning (SFS)  
UHR and FEP performed worse on 
ToM tasks than healthy controls, and 
trend-level difference between UHR 
and FEP.  
After controlling for premorbid IQ, 
difference in performance between 
ARMS and HC no longer significant. 
SC = Social cognition, ER = emotion recognition, ToM = Theory of mind, AB = Attribution Bias, SP = social perception, FO = Functional outcome measures:, 
GAF=global functioning scale, GFS-S/R =global functioning scale social/role, SOFAS=social and occupational functioning scale, SFS=social functioning scale, 
AQoL18=Assessment of Quality of Life, PSP=personal and social performance scale, HiSoC=High Risk Social Challenge, SRS-A=social responsiveness scale – 
adult, SAS-SR=social adjustment scale self-report, SC Measures: FELT = facial emotion labelling task, FEIT=facial emotion identification task, FEDT=facial 
emotion discrimination task, AP=Affective prosody, FBT=false belief tasks, RME=Mind in the eyes, TASIT = Task of Social Inference Test, ANSIE= Adult 
Nowicki Strickland Internal External LOC, IPSAQ= Internal, Personal and Situational Attributions Questionnaire, SCSQ= social cognition screening 
questionnaire Other: HC=healthy control, FEP=first episode psychosis, SCZ=Schizophrenia, CHR-N= clinical high-risk negative  
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Social Cognition and Functioning Domains 
 
Ten different measures of functioning were used, which were classified according to 
previously identified domains (Couture et al., 2006). Nine were measures of 
community functioning of which four were self-report measures and one of social skill. 
Five studies used one measure of functioning and the remaining six studies used 
between two and seven measures of functioning. See Appendix 1.5 for a summary of 
functioning measures. 
 
Eight papers examined one domain of social cognition, while the remaining three 
studies examined between two and four domains. ER was measured in eight of the 
studies, ToM in five, AB in three, and SP in one study. Two studies also looked at a 
composite social cognitive variable (comprising four domains).  
 
Emotion Recognition 
 
Seven papers directly examined facial ER and functioning, of which three looked at 
recognition from tone of voice in addition to facial expression. Only one paper found 
no association between facial or vocal ER and functioning (Cotter et al., 2017). It 
should be noted this paper had a small sample (N=30) and used a measure of ER which 
has been criticised for poor reliability.  
 
Five of eight papers found an association between functioning and accuracy of facial 
emotion recognition (Barbato et al., 2013, Glenthoj et al., 2016, Haining et al., 2019), 
speed of emotion recognition (Glenthoj et al., 2018, Haining et al., 2019) and ability to 
learn on a test-retest ER paradigm (Clayson et al., 2019). Two of these papers (Glenthoj 
et al. 2016, Haining et al. 2019) found that negative rather than positive emotions were 
associated with functioning. Haining et al. (2019) found that better ER of negative 
emotions was associated with better functioning, while Glenthoj et al. found the 
opposite of this.  
 
Haining et al. (2019) and Glenthoj et al. (2018) found that speed of facial ER was 
associated with functioning. Haining et al. (2019) found that latency in addition to 
accuracy significantly predicted 11% of role functioning variance. Glenthoj et al. 
(2018) found that latency predicted global, social and interpersonal and role 
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functioning but that accuracy no longer predicted functioning, in contrast to their earlier 
paper (Glenthoj et al. 2016). Glenthoj et al. (2018) found that after controlling for 
cognitive processing speed, ER latency was only associated with social functioning. 
Haining et al. (2019) found that cognitive processing speed predicted 5% of the 
variance in role functioning but did not control for its effect on ER latency. 
 
Clayson et al. (2019) found that patients’ categorisation as learner or non-learner in a 
test-retest paradigm correlated with role functioning. However, they did not find an 
association between any other measures of ER and functioning including pre or post 
training scores or gains scores. Given the association between role functioning and 
cognitive processing in other studies, this association with learners and non-learners 
may also be influenced by this.  
  
Three papers looked at ER from tone of voice. Amminger et al (2013) found that after 
controlling for negative and depressive symptoms, worse vocal ER contributed 3% of 
unique variance to global functioning. Two papers found no association between vocal 
ER and functioning (Cotter et al., 2017, Barbato et al., 2013). Limitations with Cotter et 
al. are discussed above, and Barbato et al. relied solely on self-reported functioning 
which has limitations in reliability. 
 
Additionally, in a subsection of the sample described in Amminger et al., 
Bartholomeusz et al. (2014) found that larger left amygdala volume in females 
mediated a relationship between better sadness recognition and worse functioning. But, 
given that the measure used (GAF) conflates symptoms with functioning, this 
relationship could represent a more general relationship with overall psychopathology 
than functioning per se. This is supported by the fact that in the same sample, 
symptoms accounted for 62% of variance in GAF scores, and amygdala volume also 
mediated a relationship between sadness recognition and symptoms. 
 
Theory of Mind 
 
Three studies found an association between ToM ability and functioning (Glenthoj et 
al., 2016, Cotter et al., 2017, Barbato et al., 2013), however in two studies (Glenthoj et 
al. 2016, Barbato et al. 2013) this was with a self-report measure, one of which was a 
measure of social responsiveness design to detect autism traits. Glenthoj et al. (2016) 
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reported non-signification associations with 4 observer-rated measures of functioning. 
Two studies found no association between ToM (Stanford et al., 2011, Ohmuro et al., 
2016), both of which were highest rated on the CCAT, although Ohmuro et al. (2016) 
only had 36 participants.  
 
Attribution Bias 
 
One study found as association between AB and functioning (Glenthoj et al., 2016) 
however AB appears to be conflated with ToM based on the scoring description 
provided. DeVylder et al. (2013) and Cotter et al. (2017) found that AB did not 
correlate with functioning, although these studies may have lacked power due to 
sample size. Overall, the AB measures used had poor psychometric properties. 
 
Social Perception 
 
Cotter et al. (2017) found that SP was not significantly correlated with functioning 
although there was a trend association between MSCEIT and SOFAS. Given the small 
sample size the study may have lacked power.  
 
Composite Social Cognition Variable  
 
Barbato et al. (2013) found that overall social cognition was associated with 
functioning but that this was no longer significant after neurocognition entered the 
model, with social cognition and neurocognition becoming more strongly associated. 
Cotter et al. (2017) found no associated between a composite social cognition variable 
and functioning.  
 
Comparison with Controls  
 
Five studies included a control group with mixed findings. Haining et al. (2019) found 
that ER latency but not accuracy was impaired relative to healthy controls. Glenthoj et 
al. (2016) found that the UHR group had worse accuracy than healthy controls. Two 
studies found that ToM was impaired relative to a control group (Ohmuro et al., 2016, 
Stanford et al., 2011) but that this difference was no longer significant after controlling 
for IQ while a third study found that ToM was impaired relative to controls but did not 
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control for IQ (Glenthoj et al. 2016). Interestingly, Stanford et al. found that ToM 
performance was impaired relative to an older control group, better than a 
schizophrenia control group, but that performance was comparable to an age matched 
younger control group. Finally, one study found that AB was impaired relative to 
controls (Glenthoj et al. 2016) while another found no difference (DeVylder et al., 
2013). 
 
Discussion  
 
This review is an update of the findings presented by Cotter et al. (2014) on the 
relationship between social cognition and functioning in UHR individuals, including an 
additional nine studies. Although 11 papers were identified, eight of these had 
overlapping samples and were drawn from RCT or longitudinal studies. There was an 
overall lack of description of how subsections or sub-samples were selected or the 
extent to which analyses were a priori. This could increase the risk of both sample 
selection and publication bias, although a number of these studies did report non-
significant findings. More studies from independent research groups are needed to 
improve generalisability of these findings, with the description and publishing of a 
priori analysis plans for baseline data being routine.  
 
Is social cognition associated with functioning?  
 
The strongest evidence was for the association between ER and functioning, with 
accurate and faster identification of negative facial emotions leading to better 
functioning with small to medium effects sizes (r=0.17-0.36). This is in keeping with 
the association between ER and functioning in schizophrenia (Fett et al., 2011; 
estimated average correlation r=0.31). Although in schizophrenia patients cognition 
and social cognition have been demonstrated to be partially independent (Schmidt et 
al., 2011), processing speed seems to be an important mediating factor between ER and 
functioning in these studies. It may be that the ability to process information quickly is 
important for successful real-world functioning, and it may be that this is particularly 
important when processing social information as interactions often occur quickly 
(Glenthoj et al., 2018).  
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Interestingly, one study found that worse identification was associated with better 
functioning, but this was in relation to self-reported quality of life. Narvaez et al. 
(2008) suggests that better neuropsychological functioning may lead to decreased self-
reported wellbeing and it may be that better social cognitive abilities allows for greater 
social comparison and decreased quality of life. Harvey et al. (2013) reported that self 
and observer reported functioning do not correlate with one another, and that self-
reported functioning may not be a reliable estimate of functioning. Studies could 
improve their findings by reporting on a combination of functioning measures.  
 
There was limited evidence that ToM was associated with functioning in these UHR 
samples, with two high quality studies finding no association, and a further study 
finding an association with an autism screening tool but not with other functioning 
measures. The evidence also does not support an association between either AB or SP 
and functioning. This conclusion is limited  by the small number of studies looking at 
these domains and known issues with AB measurement - an expert panel recently 
concluded that no existing measures of AB were psychometrically satisfactory 
(Pinkham et al., 2015).  
 
Pathways to poor functioning are thought to be multi-faceted, and the amount of 
variance explained by social cognition in these studies suggests unaccounted factors.  
In both the present studies and previous 2014 review, negative symptoms and 
processing speed significantly predicted functioning. However, many studies in the 
present review did not measure or control for these variables. In schizophrenia, there is 
evidence to suggest that social cognition mediates a relationship between cognition and 
functioning and while one study in the present review did not find support for this 
relationship, there were methodological limitations which warrant further investigation 
(Barbato et al., 2013, Schmidt et al., 2011).  
 
A lack of evidence for an association between ToM, AB and SP and functioning 
contradicts findings in patients with schizophrenia. It may be that the limited number of 
studies and methodological limitations prevented detection of this association. It could 
also be due to the lack specificity in the UHR criteria. A large percentage of individuals 
go on to develop another axis one disorder, and symptoms in at risk states are 
hypothesised to represent more general psychopathology (van Os, 2013). Given the 
hypothesised relevance of social cognitive processing in the development of psychotic 
26 
 
disorders (Frith, 1992), it may be that social cognitive deficits are more marked and 
more associated with functioning in those individuals who go on to develop 
schizophrenia spectrum disorders.  
 
The case for early intervention 
In individuals with schizophrenia, social-cognitive interventions have been shown to be 
effective in addressing both social cognitive deficits and difficulties with real-world 
functioning (Bordon et al., 2017). An association between social cognition and 
functioning in UHR individuals would indicate that such interventions could also be 
effective for this population. This review indicates that there is some preliminary 
evidence that there is an association between ER and functioning, however this is based 
on a limited number of studies which are cross-sectional by design. Longitudinal 
research is required to address causality and the direction of this association, to aid our 
understanding as to whether social cognitive interventions could be of benefit in 
improving functioning in UHR populations.  A causal link between social cognitive 
abilities such as ER and functioning would also be in keeping with findings that 
emotion recognition abilities have been shown to predict later conversion to psychosis 
(Allot et al. 2014). The neurodevelopmental model of schizophrenia suggests illness is 
in part the result of abnormal development of e.g. cognitive processes (Murray and 
Lewis, 1987) and longitudinal studies could also seek to address the role of both social 
cognitive difficulties and functioning in potential pathways to developing schizophrenia 
spectrum illnesses.  
 
Additionally, Pantelis et al. (2015) theorised that neurodevelopmental deficits may 
occur in early adulthood as well as childhood, and early interventions should 
differentiate between remediating existing deficits and preserving areas of unaffected 
ability. It appears that differences in ToM ability between UHR and healthy controls in 
these samples was mediated by both age and IQ. It is theorised that ToM develops in a 
hierarchical fashion with more advanced abilities developing later with these being 
more likely to be impaired in schizophrenia (Harrington et al., 2005). The lack of 
association between ToM and functioning could be due to the age of the UHR samples, 
with ToM abilities not yet sufficiently impaired so as to be associated with functioning. 
Longitudinal studies could address at what stage ToM becomes impaired with 
functional consequences and explore whether interventions to preserve ToM abilities 
could also be beneficial.  
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Limitations 
 
Variability in measurement and statistical analysis precluded the use of meta-analytic 
techniques which would have allowed for an estimation of effect size across studies. As 
such a narrative approach was utilised which has merit in comparing findings from 
heterogenous studies. Additionally, it was out with the scope of this review to compare 
findings across types of functioning measurement or to fully consider the effect of 
mediator or moderator variables such as gender, IQ, symptoms and cognition on the 
association between social cognition and functioning.  
 
Future Directions 
 
Future studies could improve the comparability and reliability of findings by employing 
expert recommended measures of social cognition. Functioning measurement could be 
improved with the use of both self and observer rated functioning which avoid 
conflation of symptoms with functioning. Longitudinal studies could clarify at what 
stage social cognitive deficits begin to impact on functioning and address issues of 
causality. This could help to disentangle relationship between social cognition and 
other key predictors such as cognition and symptoms and pathways to poor functioning. 
Finally, social cognitive interventions may be beneficial in preventing or remediating 
social cognitive deficits and thus improve functioning but this remains to be 
determined.  
 
Conclusions 
 
UHR individuals are a group at risk of significant social adversity and functional 
disability regardless of transition to schizophrenia. This review clarifies the relationship 
between social cognition and functioning based on the available evidence, with some 
clear evidence emerging regarding the relationship between functioning and ER.   
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Plain English Summary  
 
Background: People with schizophrenia spectrum illnesses are known to have 
difficulties with their everyday functioning, including in their work and social lives. 
This is likely to affect those individuals who are in inpatient rehabilitation services to a 
greater extent. We know from previous research that social cognitive ability – that is 
our ability to understand what others and thinking and feeling and interpret social rules 
– determines how well someone is able to function. This study was interested in 
understanding how this social cognitive ability is related to another important predictor 
of functioning – negative symptoms which are deficits in experiences such as 
motivation and enjoyment, and reduced expression of emotion. We hoped to 
understand whether social cognition and functioning are more closely related to 
experience rather than expression negative symptoms. This could help us to understand 
whether people with difficulties in processing social information are more likely to 
have poor motivation, and understand how this impacts on their functioning and overall 
recovery.  
Methods: 11 patients with a diagnosis of schizophrenia or schizoaffective disorder 
were recruited from Greater Glasgow and Clyde Rehabilitation Services. Participants 
were asked to complete a one-off testing session lasting between 90-120 minutes in 
which they completed a series of cognitive and social cognitive tasks and an interview 
about negative symptoms. Their named nurse was interviewed to obtain a rating of 
their functioning.   
Results: Due to the number of people who participated we were not able to test all of 
our hypotheses. We found that there was a trend for people with higher levels of 
experiential negative symptoms to have worse social cognitive ability and worse 
functioning. There did not seem to be an association between these factors and 
expressive negative symptoms. Because of the significant difficulties with recruitment 
we decided to include an additional aim of looking at feasible it was to recruit from the 
rehabilitation wards. We found 33% of eligible patients decided to participate. Data on 
new admissions to the wards was obtained which indicated that an estimated 14 eligible 
people would be admitted in a year and if 33% of those decided to participate, 4 
additional people could be recruited a year.  
Discussion and Implications: . Although our sample was small and findings should be 
interpreted with caution as they may not generalise, we found patterns in the data which 
suggests that different types of negative symptoms are associated with other key 
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predictors of functioning, and functional ability itself. This has important implications 
for understanding how poor functioning might occur. This may indicate that motivation 
and how good we are at processing social information are importantly related to how 
well we perform day to day.. We found that recruiting from a rehabilitation population 
was challenging, and to recruit enough participants to test some of our hypothesis 
would likely require a significant amount of time and resources. Making the testing 
session shorter and improving how we frame research to patients might enhance 
recruitment rates. This study provides important information about patterns in the data 
which would be important to replicate and extend in a larger inpatient sample and we 
provide information on the resources which might be needed to do this. Furthering our 
understanding of this in a larger inpatient sample could help us to understand how to 
develop more effective psychosocial interventions and improve the day to day 
functioning of people who require the most complex care.   
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Abstract 
 
Background: Functional disability represents a significant barrier to recovery in 
people with schizophrenia, often impacting those in in-patient rehabilitation to the 
greatest extent. There is evidence that social cognition is an important predictor of 
functional outcomes but the relationship between social cognition and functioning and 
other key variables such as symptoms remain unclear. Previous research has examined 
negative symptoms as a unitary construct. This study aims to clarify whether there is a 
differential association between experiential and expressive symptoms, functioning and 
social cognition, and whether experiential negative symptoms mediate a relationship 
between social cognition and functioning. 
Methods: 11 participants with schizophrenia or schizoaffective disorder were 
recruited. Participants were administered a battery of cognitive, social cognition and 
symptoms measures and an observer rated measure of functioning was completed with 
a named nurse.  
Results:. Due to the sample size obtained, data was visually examined and Spearman’s 
Rho correlations used to estimate effect sizes of linear relationships.. Higher levels of 
experiential but not expressive negative symptoms appeared to be associated  with 
poorer social cognitive ability and worse functioning.. Due to recruitment challenges, 
post-hoc exploration of recruitment feasibility was conducted which demonstrated that 
recruitment figures were poor with only 33% of eligible patients participating. Ward 
turnover rates were low and indicate long recruitment periods to be necessary to recruit 
adequate samples 
Discussion and conclusion: The small sample reflects the difficulty of testing 
predictors of functioning in people who, by definition, do not readily engage in 
everyday roles. With acknowledgement of the limited generalisability, these  
preliminary data suggest a differential association between experiential and expressive 
negative symptoms and their relationship to functioning and social cognition. This 
highlights the importance of motivational constructs in determining functioning and 
may be a potential pathway from social cognition to functioning. Suggestions are made 
to address the low recruitment rates and increase participation.  
 
 
Key Words: psychosis, theory of mind, feasibility, negative symptoms  
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Introduction 
 
Improving understanding of the pathways to poor functioning in schizophrenia is vital 
for developing effective psychological interventions to promote recovery, especially in 
those individuals requiring the most expensive and complex care. There is a growing 
recognition of the role of negative symptoms and how these might relate to other known 
predictors of functioning.  
 
The Functional Deficit in Schizophrenia 
 
Psychosocial functioning is significantly impaired in many people diagnosed with 
schizophrenia and is an increasingly important target within mental health services, with 
clinicians recognising the need to direct efforts beyond alleviating positive symptoms 
(Brissos et al., 2011). Positive symptoms are often those which bring people to the 
attention of services and to an inpatient admission, but poor psychosocial functioning 
often leads to poorer recovery from these episodes and, for some people, admission to 
psychiatric rehabilitation services. Functioning is defined as an individual’s ability to 
perform the activities of daily living in key areas of life such as social and interpersonal 
functioning, recreation, occupation and self-care, as well as their perceived level of 
satisfaction or quality of life (Priebe, 2007). Around 10% of individuals with 
schizophrenia have poor long-term functioning and complex care needs which account 
for an estimated 25-50% of mental health spending in the UK (Department of Health, 
2012). This type of care requiring intensive input with admissions of more than 18 
months (Joint Commission Panel for Mental Health, 2016). There is a clear need for 
improved interventions to support recovery of functioning which has directed research 
efforts towards (1) understanding the predictors of functioning; (2) understanding the 
potential mechanisms leading to poor functioning.  
 
Predictors of functioning 
 
Two of the most consistently reported predictors of functioning in schizophrenia are 
cognition and social cognition (Green, 1996, Green et al., 2000, Fett et al., 2011). 
Cognition refers to our ability to think and reason such a memory, processing speed, 
attention. Social cognition refers to processes which specifically underly complex social 
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interactions (Adolphs, 2001) Cognition domains including secondary verbal memory, 
immediate memory, executive functioning and vigilance accounts for 20-60% of 
variance in functioning (Green et al., 2000). Similarly, there is strong evidence that social 
cognition significantly contributes to functional outcomes. A narrative review by 
Couture et al. (2006) identified social perception (SP) and emotion recognition (ER) to 
be significantly associated with functioning. Fett et al. (2011) quantified these findings 
in a meta-analysis of 52 studies, demonstrating mean correlations between domains of 
social cognition and functioning ranged from 0.2 to 0.4 with the largest effect size found 
between community functioning and Theory of Mind (ToM). Further research has 
concluded that social cognition has effects on functioning that are independent of the 
effects of cognition alone (Allen et al., 2007, Sergi et al., 2007, van Hooren et al., 2008). 
A meta-analysis by Schmidt et al. (2011) of 15 studies found that 25% of variance in 
functioning is explained by a model whereby social cognition mediates the relationship 
between neurocognition and functioning. 
 
These findings have begun to shed light on the potential pathways to poor functioning, 
with important implications for interventions such as the development of cognitive and 
social cognitive remediation programmes. However, it remains the case that relatively 
small amounts of variance are accounted for by these factors (~25%) and intervention 
programmes do not always generalise to real world functioning with improvements often 
not sustained beyond the intervention (Wykes et al., 2011, Tan et al., 2018). This suggests 
that other important factors need to be examined in understanding the pathway to poor 
functioning such as understanding causal relationships in order to improve future 
interventions.  
 
The Functional Importance of Negative Symptoms  
 
Negative symptoms have been recognised as a hallmark feature of schizophrenia since 
its initial conceptualisation (Kraeplin, 1919) and the NIMH-MATRICS Consensus 
Statement on Negative Symptoms affirmed their importance important as a treatment 
target (Kirkpatrick et al., 2006). Negative symptoms refer to absence of behaviours and 
experiences including alogia, blunted affect, apathy, avolition and anhedonia which were 
originally characterised as a unitary domain. Recent factor analysis research points 
towards a two-factor conceptualisation of negative symptoms: expressive deficits 
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including blunted affect and alogia, and experiential deficits, including apathy, avolition 
and anhedonia (Blanchard and Cohen, 2005). 
 
Negative symptoms are an important predictor of psychosocial outcomes with a meta-
analysis of 52 studies reporting a mean correlation of 0.4 between negative symptoms 
and functioning. Additionally, there is strong evidence to suggest that negative symptoms 
act as a mediator between cognition and functioning (Ventura et al., 2009). Foussias et 
al. (2011) found that motivation accounted for between 72 -74% of functional outcome 
at baseline and 6-month follow up. Additionally, Leifker et al.(2009) found that apathy 
was related to real-world behaviour independent of functional capacity (i.e. necessary 
skills). Hence it is possible that deficits in cognitive abilities lead to failures in 
performance which reduce the motivation to pursue similar goals in the future, regardless 
of functional capacity to do so, thus leading to the observable functional deficits.  
Defeatists performance beliefs such as “If you cannot do something well, there is little 
point in doing it at all” have been found to mediate a relationship between cognition and 
both functioning and negative symptoms (Grant and Beck, 2008, Weissman, 1979). This 
points to a potential mechanism between cognitive deficits, negative symptoms and 
functioning, consistent with theories of motivation in human behaviour regarding 
expectation of success (Grant and Beck, 2008). This may mean that even when someone 
relearns a skill (e.g. through cognitive remediation) this may not translate to everyday 
behaviour without the relevant beliefs and motivation to support this.  
 
Negative Symptoms and Social Cognition 
 
There has been relatively little research into the relationship between negative symptoms 
and social cognition. Theoretically this relationship is likely to be a complex one, as 
lowered motivation could partially disrupt the development or display of social cognitive 
abilities, but social cognitive deficits could also contribute to lowered motivation to 
engage in social interactions (Marder and Galderisi, 2017). There is some limited 
evidence to suggest that social cognition and negative symptoms are related to one 
another. Lincoln et al. (2011) found that social cognition including ToM, empathy, and 
attribution bias accounting for 54% of variance in negative symptoms in individuals with 
low self-esteem. Sergi et al. (2007) also found evidence for a small correlation between 
emotion recognition and negative symptoms. Two studies to date have looked at whether 
negative symptoms mediate a relationship between social cognition and negative 
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symptoms with Lin et al. (2013) finding support for this hypothesis while Couture et al. 
(2011) did not.  Social skills training programmes have been shown to improve negative 
symptoms and functioning with small to medium effect sizes and this is thought to be 
mediated by defeatist performance beliefs (Granholm et al., 2017, Turner et al., 2014).  
 
In understanding how social cognitive abilities relate to negative symptoms and how this 
might guide further interventions efforts, we need to understand whether different 
domains of negative symptoms relate differently to social cognitive abilities. Previous 
studies of this relationship have measured negative symptoms as a unitary construct or 
examined amotivation in isolation without comparison to expressive deficits. 
Theoretically, it may be that avolition and apathy are more associated with social 
cognition than expressive deficits based on the relevance of social cognitive abilities for 
motivated social behaviour. This is supported by the finding that social skills training 
improved experiential but not expressive negative symptoms (Granholm et al. 2014).  
However, appropriate social signalling is also thought to be important for overcoming 
negative symptoms (Elis et al., 2013). Understanding whether there is a differential 
relationship between different types of negative symptoms, social cognition and 
functioning and whether negative symptoms act as a mediator  will provide important 
information regarding potential pathways to poor functioning and could inform the 
development of psychosocial interventions.  
 
Aims 
 
We wish to clarify the relationship between social cognition, functioning and two distinct 
domains of negative symptoms – experiential and expressive, and to determine whether 
negative symptoms mediate a relationship between social cognition and functioning. We 
aim to explore the relative predictive contribution of these variables to functioning 
through testing a regression model.  
 
 
We hypothesise that: 
 
1. Social cognitive ability will be positively correlated with functioning. 
2. Greater levels of experiential but not expressive negative symptoms will be 
negatively correlated with functioning. 
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3. Greater levels of experiential but not expressive negative symptoms will be 
negatively correlated with social cognition. 
4. Experiential negative symptoms will mediate a relationship between social cognition 
and functioning.  
 
In addition to these specific hypotheses we aim to explore the relative contributions of 
executive functioning, social cognition and negative symptoms to functioning through 
testing of a regression model. 
 
 
Methods 
 
Participants 
 
Participants were eligible to participate if they (a) had a diagnosis of schizophrenia or 
schizoaffective disorder, (b) aged between 18-65 years, (c) no medication changes for 
past 4 weeks, (d) ability to provide informed consent, (e) fluent in English. Participants 
were excluded who (a) had a history of significant head injury, (b) intoxication at time 
of testing, (c) IQ below 75 or established learning disability, (d) other diagnoses that 
affect cognition (e.g. dementia).  
 
Recruitment 
 
Recruitment took place between April and June 2019 from Greater Glasgow and Clyde 
Rehabilitation Wards. Screening was carried out by named nurses who provided 
eligible participants with verbal information about the study and invited them to be 
approached by the primary researcher. Participants agreeing to an initial approach met 
with the researcher on the ward and were given an information sheet (Appendix 2.1). 
The researcher verified the patient’s capacity to give informed consent. Participants 
were given a minimum of 24 hours before being asked to provide written informed 
consent. Those who declined an initial approach were offered the opportunity to meet 
with the researcher at a future ward visit unless they expressly declined future 
approaches. The rationale for this was to account for variability in patients’ mental 
states between ward visits.  
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Measures 
 
Clinical Information and Symptomology 
Consultant Psychiatrists provided verification of the diagnosis. Duration of illness, 
length of admission and prescribed medication were obtained from medical records. 
 
Negative symptoms were assessed using the Clinical Assessment Inventory of Negative 
Symptoms (CAINS; Kring et al., 2013), a 13-item semi-structured interview yielding 
two domains– motivation and pleasure (MAP) and expressive symptoms (EXP). The 
CAINS was administered by the researcher and audio recorded for retrospective 
scoring. Amotivation and anhedonia were measured using self-report questionnaires. 
The Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS; Gooding 
and Pflum, 2014), a 17-item questionnaire with higher scores indicating greater 
capacity to anticipate and enjoy interpersonal interactions. The Temporal Experience of 
Pleasure Scale (TEPS; Gard et al., 2006), an18-item questionnaire with higher scores 
denoting greater capacity to gain pleasure from experiences in the moment and in the 
future.  
 
The Depression Stress and Anxiety Scale (DASS-21; Lovibond and Lovibond, 1995) 
(Lovibond and Lovibond, 1995; DASS-21), a 21-item self-report questionnaire with 
higher scores indicate more severe symptoms in each domain.  
 
Social Cognition 
Social cognitive domains were selected on the basis of previous literature (Sergi et al., 
2007, Lincoln et al., 2011), with measures selected on the basis of psychometric 
properties (Pinkham et al., 2015). ToM was assessed using The Hinting Task (Corcoran 
et al., 1995). Participants were read ten vignettes wherein one character drops a “hint” 
to another with participants asked to identify the true meaning. A correct response 
scores two points; incorrect responses are followed up with an additional hint with 
correct responses following this scoring one point. Emotion recognition was assessed 
using the Bell Lysaker Emotion Recognition Task (BLERT; Bryson et al., 1997). 21 
ten-second video clips of an actor talking are shown to participants who select the 
emotion the actor is feeling from a response card with 7 possible emotions – happiness, 
sadness, anger, surprise, disgust, fear or no emotion. One point for each correct answer.  
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Neurocognition 
Executive functioning measures were selected on the basis of previous study addressing 
similar research questions (Konstantakopoulos et al., 2011). The Trail Making Task 
Part B (TMT-B) requires participants to connect letters and numbers in ascending and 
alternating order. Performance is measured by completion time (seconds) with faster 
time indicating better performance. Phonemic fluency (Benton and Hamsher, 1983) 
requires participants to produce words beginning with the letters F, A and S in one 
minute. More words indicate better performance. 
 
Psychosocial Functioning 
Functioning was assessed using the Personal and Social Performance Scale (PSP) 
(Morosini et al., 2000) which provides an overall measure of observer rated functioning 
based on four domains: (a) socially useful activities, (b) personal and social 
relationships, (c) self-care, (d) disturbing and aggressive behaviours. The reference 
period was the previous four weeks. The UCLA loneliness scale (Russell et al., 1980), 
is a 20 item self-report questionnaire with lower scores indicating greater subjective 
loneliness.  
 
Procedures 
 
All procedures were approved by the East of Scotland Research Ethics Service 
(Appendix 2.2 and 2.3). All participants provided written informed consent. A single 
test session was conducted at the ward lasting between 90-120 minutes. All measures 
were administered by the primary researcher. The participants named nurse was 
interviewed within two weeks to obtain a rating of functioning using the PSP.  
 
Statistical Analysis 
 
All data were analysed using SPSS Version 26. Demographic characteristics were 
described using mean and standard deviation. Associations between key variables were 
examined visually using scatterplots. As variables were not normally distributed and 
the sample size small, non-parametric tests were used. Two-tailed Spearman’s Rho 
correlations were calculated between key variables of social cognition, negative 
symptoms and functioning for estimations of effect sizes.  
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 Results 
 
Sample Characteristics 
 
Sample characteristics are shown in Table 1. Eleven participants (7 male) with 
schizophrenia (N=9, 82%) or schizoaffective disorder (N=2, 18%) with an average 
illness duration of 16 years participated. All were white British with the exception of 
one white Polish participant. Rehabilitation admission was on average 14.5 months, 
and the total duration of inpatient admission, including prior acute, continuing care or 
forensic admission was 4.1 years. In addition to antipsychotic medication, five 
participants took an antidepressant and 6 participants were prescribed mood stabilisers.  
The neurocognitive and symptom characteristics are shown in Table 2.  
 
Table 1:  Sample Demographics 
 Mean SD 
Participants (N) 11 - 
Male (%) 7 (64) - 
Schizophrenia (%) 9 (82) - 
Age (Years) 39.36 7.7 
Illness Duration (Years) 16.1 9.5 
Rehabilitation Admission (Months)  
14.5 17.2 
Total inpatient admission (Months) 
50.2 80.8 
Atypical Antipsychotic (N)    
Clozapine 9 - 
Paliperidone 1 - 
Typical Antipsychotic (N)   
Zuclopenthixol 1 - 
Adjunctive Antipsychotic (N)    
Amisulpiride 2 - 
Risperidone 1 - 
Aripiprazole 1 - 
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Table 2 Neurocognitive and Clinical Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Mean SD Possible Range 
Negative Symptoms    
 CAINS Total 21.77 2.89 0-52 
 CIANS MAP 16.09 7.45 0-36 
 CAINS EXP 5.64 4.13 0-16 
 ACIPS 85.55 11.44 17-102 
 TEPS Total 85.36 14.86 18-108 
Other Symptoms    
 DASS 21 – Total 24.73 20.96 0-63 
 Depression 7.82 2.40 0-21 
 Anxiety 7.45 2.17 0-21 
 Stress 9.45 2.32 0-21 
Psychosocial Functioning    
 PSP (Total)  43.73 18.54 0-100 
 PSP – socially useful 2.82 0.87 0-5 
 PSP – Personal and social  2.64 1.03 0-5 
 PSP -  Self care 1.64 1.36 0-5 
 PSP – Disturbing and aggressive 1.36 1.12 0-5 
 UCLA Loneliness Scale 41.70 7.70 20-80 
Neurocognition    
 TMT-B (seconds)  167.82 123.21 - 
 TMT-B Z-score 7.06 - - 
 Phonemic Fluency – N correct 31.91 12.55 - 
 
Phonemic Fluency 
 Z score 
-0.92 - - 
Social Cognition    
 Hinting Task Total  10.55 6.73 0-20 
 BLERT Total Correct 12 4.47 0-21 
 BLERT Positive Correct 4 1.61 0-5 
 BLERT Negative Correct 3.91 1.76 0-5 
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Relationship between Social Cognition, Negative Symptoms and Functioning 
 
Hypothesis 1: Social cognitive ability will be positively correlated with functioning 
 
We hypothesised that Theory of Mind and Emotion Recognition abilities would be 
positively correlated with functioning. Scatterplots of these relationship are shown in 
Figure 1.  These show a moderate positive linear relationship between performance on 
social cognitive measures and PSP ratings of functioning. Better functioning appears to 
be associated with better performance on social cognitive tasks. This relationship is 
stronger for performance on the Hinting Task, than for the BLERT. There were two 
outliers for BLERT and functioning – with one participant scoring higher than would 
be expected based on functioning performance, and one scoring lower than would be 
expected. There were no significant outliers for the hinting task and functioning 
variables.  
 
Spearman’s Rho correlations showed that the correlation coefficient between the 
Hinting Task and functioning was r= 0.87 and the correlation coefficient between 
BLERT and functioning was r=0.65.  
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Figure 1: Scatterplot of social cognition and functioning variables 
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Hypothesis 2: Experiential but not expressive negative symptoms will be negatively 
correlated with functioning 
 
Figure 2 shows scatterplots of the relationship between experiential and expressive 
negative symptoms and functioning. Higher scores on the CAINS MAP and CAINS 
EXP indicate worse negative symptoms. The scatterplots suggest that in this sample 
there is a strong, negative linear relationship between experiential negative symptoms 
and functioning, but there appears to be no relationship between expressive negative 
symptoms and functioning. There was one outlier who had low experiential negative 
symptoms but also scored low on functioning.  
 
 
0
2
4
6
8
10
12
14
0 10 20 30 40 50 60 70 80 90
C
A
IN
S 
Ex
p
re
ss
io
n
 S
co
re
Personal and Social Performance Scale Score
0
5
10
15
20
25
30
0 10 20 30 40 50 60 70 80 90
C
A
IN
S 
M
o
ti
va
ti
o
n
 a
n
d
 P
le
as
u
re
 S
co
re
Personal and Social Performance Scale Score
Figure 2: Scatterplot between Negative Symptoms and Functioning 
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Spearman’s Rho correlations showed that the association between experiential negative 
symptoms and functioning was r= -.87 while the association between expressive 
negative symptoms was r= -.04. In this small sample there appears to be a differential 
association between functioning and experiential and expressive negative symptoms.  
 
Hypothesis 3: Greater levels of experiential but not expressive negative symptoms will 
be negatively correlated with social cognition 
 
We hypothesised that higher levels of experiential negative symptoms would be 
negatively correlated with social cognitive performance, but that this association would 
not be present with expressive negative symptoms. Figure 3 and 4 show scatterplots of 
the association between Theory of Mind and emotion recognition performance and 
negative symptoms. For Theory of Mind, there is evidence for a negative, liner 
association with experiential negative symptoms with better performance on the hinting 
task being associated with lower CAINS MAP scores.. There is no apparent 
relationship with expressive negative symptoms.  
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Regarding emotion recognition, there does not appear to be a linear relationship with 
expressive negative symptoms. There appears to be a moderate negative linear 
association with experiential negative symptoms, with better performance on the 
BLERT being associated with lower levels on the CAINS motivation and pleasure 
scale. The relationship between emotion recognition and experiential negative 
symptoms appears weaker than the relationship with hinting task performance.  
 
Spearman’s Rho correlations between social cognitive task performance and negative 
symptoms are shown in Table 3. This also suggests that in this small sample there is an 
indication of a differential association between social cognitive task performance and 
different domains of negative symptoms, with better performance on social cognitive 
tasks being associated with lower levels of experiential negative symptoms.  
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Table 3 Spearman's Rho Correlations between social cognitive task performance and negative symptoms 
Social Cognitive Task  CAINS MAP Score CAINS EXP Score 
Hinting Task r=-0.89 r=-0.02 
Emotion Recognition r=-0.77 r=-0.12 
 
 
Additional Hypothesis and Aims 
 
Due to the small sample size  obtained, we were unable to test our hypothesis that 
negative symptoms would mediate a relationship between social cognition and 
functioning. We were additionally unable to construct a regression model to test the 
relative predictive contribution of these variables to functioning.  
 
Post-Hoc Analysis of Recruitment Feasibility 
 
Due to challenges with recruitment which led to the small sample size obtained for the 
current study, an additional post-hoc exploration of recruitment feasibility was carried 
out. Figure 5 shows a flowchart of participant recruitment. A total of 69 patients were 
inpatient in Glasgow City rehabilitation services between April and June 2019. Thirty 
patients were ineligible after screening with a further 6 deemed ineligible by the 
researcher, leaving 33 eligible participants (48%). Nineteen (57%) eligible patients 
agreed to an approach by the researcher and 11 (33% of eligible patients) participated. 
This represented 16% of the in-patient population within the recruitment period. 
 
Additional data was sought from the wards regarding patient turnover to determine the 
feasibility of increased recruiting figures with an extended recruitment period. Two of 
the five wards responded; the North West sector reported an average annual turnover 
from two wards as 7 per year which reflects a 35% annual turnover. 
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Figure 5. Recruitment and Participation Flowchart  
 
 
 
Total Patients in Glasgow City 
Rehabilitation Services between April 
and June 2019  
N = 69 
Eligible participants given 
information sheet by nursing staff  
N = 39 
Ineligible N = 30 
Reasons 
Medication Instability N= 4 
Learning Disability/IQ N= 8 
Diagnosis N= 4 
Head Injury N=4  
Capacity N=2 
Dementia/Degenerative Condition N= 2 
Regular Intoxication N=2 
Selective Mutism N=2 
Aged 65+ N=2 
Agreed to and approached by 
researcher  
N = 25 
 
Declined approach  
N = 14 
 
Declined to participate  
N= 5 
 
Deemed unable to provide 
informed consent   
N= 6 
 
Testing session arranged  
N = 14 
 
Withdrew prior to providing 
informed consent 
N=3  
 
Provided informed consent and 
completed testing session 
N = 11 
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Discussion 
 
The current study demonstrated that there may be a differential association in the 
relationship between two negative symptoms domains, social cognitive ability and 
functioning. Due to the small sample size obtained these associations were explored 
using descriptive rather than inferential statistical methods but, taken together with the 
additional information gathered regarding recruitment feasibility, the results provide 
important information for future research within this population.  
 
The Importance of a two-factor model of negative symptoms 
 
Firstly, we found that both social cognition and negative symptoms appeared to be 
associated with functioning. This is consistent with previous research which has shown 
that social cognitive ability accounts for around 25% of variance in functioning, with 
theory of mind showing the largest effect sizes (Fett et al., 2011). Examination of the 
data in this small inpatient sample suggested that ToM may have been more strongly 
associated with functioning that emotion recognition ability. Additionally, negative 
symptoms seemed to show an association with functioning, but there was a differential 
association between domains of negative symptoms. Previous research has shown that 
higher levels of negative symptoms are associated with poor functioning, but these 
studies have typically looked at negative symptoms as a unitary construct combining 
both expressive and experiential negative symptoms (Ventura et al., 2009). Other 
studies have examined apathy or motivation in relation to functioning but have not 
directly compared this with expressive negative symptoms (e.g. Foussias et al., 2011). 
This study is one of the first (to our knowledge) to suggest that experiential but not 
expressive negative symptoms are associated with functioning. This is supported by a 
recently published study of 135 outpatients which found that experiential negative 
symptoms correlated significantly with interpersonal functioning, while expressive 
negative symptoms did not (Harvey et al., 2019). Understanding the predictors and 
pathways to poor functioning has been of growing interest in schizophrenia research 
since the mid 2000’s, and the present study extends knowledge of this issue to suggest 
that when examining the role of negative symptoms in functional disability, we should 
examine negative symptoms domains separately from one another. Future studies could 
seek to extend and replicate these findings in a larger in-patient sample.  
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Secondly, our findings indicate that there may also be a differential association between 
social cognition and negative symptom domains. Specifically, the data are suggestive 
of an association between Theory of Mind ability and experiential negative symptoms, 
but not expressive negative symptoms. Although there did appear to be a pattern in the 
data for a relationship with emotion recognition, this appeared to be weaker that with 
ToM with more outliers present. Social cognitive abilities such as the ability to 
understand and recognise emotions and others mental state could be hypothesised to be 
associated with reduced expression of emotion and speech production in social 
situations (Elis et al., 2013). However, these findings suggest that this may not always 
be the case. Expressive deficits such as alogia have been found to be related to retrieval 
from verbal memory, and blunted affect has been shown to be related to a motor 
production difficulty (Alpert et al., 2000, Fervaha et al., 2016). Taken together with our 
initial findings, this suggests that expressive deficits are less related to difficulty in the 
interpretation of social information but more strongly linked to cognitive or motor 
functions, and that different neurocognitive processes may underly the expression of 
different symptoms domains.  
 
Social cognitive ability appears to be related to the motivation and pleasure constructs 
of negative symptoms which are expressed in the marked lack of drive to engage in 
meaningful activity and establish and maintain interpersonal relationship. ToM and the 
ability to represent another’s mental state has been theorised to play a key role in the 
development of positive symptoms through deficits in self and other monitoring (Frith, 
1992). What has been less fully explored is how social cognitive ability may contribute 
to negative symptom development. Previous research has suggested that defeatist 
performance beliefs may mediate a relationship between cognitive ability and negative 
symptoms and it may be that a similar relationship exists between social cognition and 
negative symptoms (Grant & Beck, 2008). One could hypothesise that poor social 
cognitive ability may contribute to similar defeatist beliefs regarding one’s ability to 
engage in successful social interactions, leading to the marked amotivation and apathy 
that is so common among individuals with schizophrenia. It may then be that these 
motivational deficits reduce the ability to perform key interpersonal and societal roles 
leading to poor functional ability. Two previous studies have found conflicting 
evidence as to whether negative symptoms mediate a relationship between functioning 
and social cognition (Lin et al., 2013, Couture et al., 2011). However, both of these 
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studies looked at negative symptoms as a unitary construct. Given these domains may 
be differentially related to social cognitive domains, examining them as unitary 
construct may have impacted on the ability to detect a mediated relationship between 
social cognition, negative symptoms and functioning.  
 
These propositions remain speculative as the present study did not obtain a large 
enough sample size to be able to test whether there was a mediated relationship 
between social cognition, experiential negative symptoms and functioning, and the 
experimental design cannot address questions of causality. However, there is evidence 
that social cognitive ability is impaired and associated with poor functioning prior to a 
first episode of active psychosis and poorer premorbid social adjustment predicts worse 
negative symptoms in later illness (Bora & Pantelis., 2013, Kelley et al., 1992). 
Additionally, social cognitive interventions have been shown to reduce experiential but 
not expressive negative symptoms, and a reduction in defeatist beliefs has been 
identified as one mechanism by which this occurred (Granholm et al., 2014, Granholm 
et al., 2017). The findings presented here could be replicated and extended in a larger 
inpatient sample which would allow some of these hypotheses to be more fully 
explored.   
 
Recruitment Feasibility 
 
A post-hoc aim of exploring recruitment feasibility was included following the 
identification of significant recruitment difficulties. We found that conversion rates 
were low, even when a sufficient number of eligible participants were approached. A 
low ward turnover of 35% presents challenges to the recruitment of a sufficient sample 
in a limited timeframe. We could cautiously assume that with full occupancy of 80 beds 
and annual turnover of 35%, over one year of recruitment, 28 new patients would be 
admitted, of which 14 (48%) could be eligible and 4.8 (33%) could be expected to 
participate based on our recruitment rates. This could be slightly higher if we assume 
that all participants would meet medication stability in the course of a year’s 
recruitment. Our initial sample size calculation indicated a required sample size of 40 
participants. Based on our recruitment figures, this would require a baseline population 
of 250 patients, or an additional 5-6 years of recruitment from the wards included in 
this study based on estimated turnover rates. It should be noted that these rates are 
based on one sector and may not be representative of other sectors. However, this is in 
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keeping with average inpatient admissions in rehabilitation wards and reflects the slow-
stream nature of this work. This provides an indication of the resources which would be 
required to recruit a sufficient sample to extend the preliminary findings discussed 
above. Future studies could seek to include additional sites (e.g. across Scotland), 
widen the inclusion and exclusion criteria or extend the available recruitment period.  
 
High refusal rates could in part be due to the marked negative symptoms which could 
reduce motivation to participate, and recruitment could be improved in a number of 
ways. Our protocol length may have deterred patients and researchers should aim to 
balance completeness of measures to test hypotheses and participant burden. We found 
that self-reported negative symptoms did not appear to be associated  with any other 
measures, including the CAINS, which contrasts with findings from out-patient 
samples (Kring et al., 2013). This may have been due to the sample size, but Harvey et 
al. (2013) has suggested that self-report measures in schizophrenia may not be as 
reliable as observer ratings, and in more impaired inpatient populations self-report 
measures may be less useful and could be excluded.  
 
Additionally, future studies could seek to understand how to engage relevant 
stakeholders to improve recruitment rates. Anecdotal evidence from this study suggests 
that staff framing the initial approach positively or negatively influenced whether 
patients agreed to meet the researcher. Of eligible participants agreeing to meet the 
researcher, 58% completed the test session. Nursing staff are often a key contributor to 
recruitment  into mental health research studies and a number of factors may contribute 
to how they view and engage with research These will need to be more fully 
understood to improve recruitment. Previous research has identified potential barriers 
to recruitment from mental health services including staff feeling that research is not 
relevant to them and their patients, clinical workloads impacting the prioritisation of 
research activity (Borschmann et al., 2014) and staff’s understanding of research aims 
and eligibility criteria (Howard et al., 2009). Additionally, a common theme emerges 
around staff feeling responsible for balancing potential harms and benefits and seeking 
to protect patients (Adams et al., 2015). Future studies should endeavour to address 
these barriers in collaboration with those who are being asked to support recruitment. 
An alternative approach to improving recruitment which reduces the burden on 
frontline staff  was proposed by Callard et al. (2014). They tested a model of “consent 
to contact” allowing direct approach by researchers which improved participation rates. 
58 
 
While innovative ideas are clearly required in order to advance research with hard-to-
reach populations, there are significant legal and ethical issues which would need to be 
taken into consideration, particularly within in-patient contexts.  
Despite these challenges, continuing research efforts in these populations is an 
important endeavour, as research often occurs with easier-to-recruit outpatient samples, 
but these findings may not generalise to the inpatient population who may have more 
marked difficulties, and tend to be the recipients of the social cognitive interventions 
which are subsequently developed.  
 
Strengths and Limitations 
 
Firstly, our small sample size reduces the generalisability of the findings and may have 
introduced bias into the sample by the participants who did choose to take part. This 
also limited our ability to conduct an inferential exploration of our hypotheses or to 
model relationships between relevant predictors of functioning. However examining 
the feasibility of recruiting from this hard-to-reach populations in combination with 
patterns present in the data has provided valuable information for the development of 
future research protocols. Secondly, due to lack of response, our turnover data is based 
solely on North-West sector and may not generalise to other sectors. Thirdly, diagnoses 
provided by the clinical team were not independently verified by the researchers and 
errors in diagnosis could have been present. However, all of the included sample were 
in-patient in long term rehabilitation services and prescribed an atypical antipsychotic, 
indicating that the sample was representative of the target population regardless of any 
diagnostic issues. Finally, social cognition is a multifaceted construct and we only 
included two domains of social cognition; however, this was in consideration of the 
length of the protocol.  
 
Strengths of this study were the use of objective measurements of functioning and 
negative symptoms which have both been designed to reduce overlap which has been a 
criticism of previous research. In particular, the CAINS has been designed to 
specifically assess internal motivation as well as external behaviours and so does not 
just reflect behaviour. A further strength is the use of social cognitive measures which 
have demonstrated high psychometric properties and have been recommended by an 
expert panel for use in schizophrenia research. 
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Future Directions 
 
Future studies could seek to replicate and extend the preliminary findings presented 
here in a larger sample of in-patients to map out the relationship between social 
cognition, negative symptoms and functioning using a two-construct model of negative 
symptoms and include additional domains of social cognition. Longitudinal studies 
could seek to clarify the nature of causal relationships, as long-term hospitalisation 
could also atrophy social cognitive abilities and this may be more marked in people 
with prominent negative symptoms. Intervention studies could examine the 
contribution of baseline experiential negative symptoms in determining outcomes in 
social cognitive remediation programmes. Given that different negative symptoms may 
be related to different underling constructs, assessing negative symptoms as a unitary 
construct may mask effects on one domain and intervention studies should take this 
into consideration.  
 
Conclusion  
 
We provide preliminary data on a potential differential association between two 
domains of negative symptoms, social cognition and functioning as well as important 
information on the feasibility of recruiting from hard-to-reach in-patient populations 
who are under-researched. Our findings are limited by our small sample and future 
studies should seek to extend these findings in a larger sample and address practical 
issues to recruitment.   
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apply. 
Charges for colour figures in print are £300 per figure ($400 US Dollars; $500 Australian 
Dollars; €350). For more than 4 colour figures, figures 5 and above will be charged at £50 
per figure ($75 US Dollars; $100 Australian Dollars; €65). Depending on your location, 
these charges may be subject to local taxes. 
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Copyright Options 
Copyright allows you to protect your original material, and stop others from using your 
work without your permission. Taylor & Francis offers a number of different license and 
reuse options, including Creative Commons licenses when publishing open access. Read 
more on publishing agreements. 
Complying with Funding Agencies 
We will deposit all National Institutes of Health or Wellcome Trust-funded papers into 
PubMedCentral on behalf of authors, meeting the requirements of their respective open 
access policies. If this applies to you, please tell our production team when you receive 
your article proofs, so we can do this for you. Check funders’ open access policy 
mandates here. Find out more about sharing your work. 
Open Access 
This journal gives authors the option to publish open access via our Open Select publishing 
program, making it free to access online immediately on publication. Many funders 
mandate publishing your research open access; you can check open access funder policies 
and mandates here. 
Taylor & Francis Open Select gives you, your institution or funder the option of paying an 
article publishing charge (APC) to make an article open access. Please 
contact openaccess@tandf.co.uk if you would like to find out more, or go to our Author 
Services website. 
For more information on license options, embargo periods and APCs for this journal please 
go here. 
My Authored Works 
On publication, you will be able to view, download and check your article’s metrics 
(downloads, citations and Altmetric data) via My Authored Works on Taylor & Francis 
Online. This is where you can access every article you have published with us, as well as 
your free eprints link, so you can quickly and easily share your work with friends and 
colleagues. 
We are committed to promoting and increasing the visibility of your article. Here are some 
tips and ideas on how you can work with us to promote your research. 
Article Reprints 
You will be sent a link to order article reprints via your account in our production system. 
For enquiries about reprints, please contact the Taylor & Francis Author Services team 
73 
 
at reprints@tandf.co.uk. You can also order print copies of the journal issue in which your 
article appears. 
Queries 
Should you have any queries, please visit our Author Services website or contact us here. 
Updated 18-05-2018 
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Appendix 1.2 Full Search Strategy: Ovid Medline 
 
 
1. psychotic disorders/ or schizophrenia/  
2. (schizophrenia or schizophrenic or psychos?s or psychotic or schizoaffective).ti,ab,kw 
3. 1 or 2   
4. prodromal symptoms/   
5. (Attenuated adj1 (psychos*s or symptoms or psychotic)).ti,ab,kw.  
6. ((High risk or at risk) adj1 (mental state or population or patient or person or group or 
individual)).ti,ab,kw.  
7. (ultra high risk or clinical* high risk or psychosis risk or at risk for psychosis or 
prodrom*).ti,ab,kw.   
8. 4 or 5 or 6 or 7  
9. "Quality of Life"/ or "Activities of Daily Living"/ or Community Participation/  
10. ((work or vocation* or occupation* or functional or psychosocial or community or social or 
prosocial or adaptive or interpersonal or global or role) adj1 (function* or adjust* or 
behavio?r* or outcome* or satisfaction)).ti,ab,kw.   
11. (quality of life or activit* of daily living or independent living skills or social 
skills).ti,ab,kw.  
12. 9 or 10 or 11  
13. "theory of mind"/ or social perception/ or facial recognition/ or facial expression/  
14. (theory of mind or false belief or tom or mentali?ing or mentali?ation or attribution* or 
social perception or social cog*).ti,ab,kw.  
15. ((Emotion or social or affect or facial) adj1 (recognition or perception)).ti,ab,kw.  
16. 13 or 14 or 15  
17. 3 and 8 and 12 and 16 
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Appendix 1.3 - Data Extraction Form 
 
1. General Information 
 
Date data extracted  
Name of person 
extracting data 
 
Title of study, 
authors and date  
 
 
2. Inclusion Criteria 
 
Criteria Location in text (e.g. Page #)  
Original research paper  
Measured social cognition – ToM, ER, 
AB, SP 
 
Measured Functioning  
Examined association between 
functioning and social cognition 
 
Population – UHR?  
Validated UHR screening tool used?  
 
3. Study Characteristics 
Number of Participants UHR (N)  
Control or other comparison group 
included (N) 
 
Study design  
Study Aims   
 
4. Demographics (UHR Sample) 
Gender (% Male)   
Age   
Education   
UHR Criteria used  
*for age and education Mean and SD 
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5. Measures  
Measures of social cognition used  
 
 
 
 
Measures of functional outcome used   
 
 
 
6. Results 
 
Measures  Statistical test Statistical 
result 
    
   
 
 
7. Comparison with control group (if relevant)?  
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Appendix 1.4: CCAT Rating for Included Studies 
Paper Preliminaries Introduction Design Sampling 
Data 
Collection 
Ethical 
Matters 
Results Discussion 
Total Score 
(%) 
Amminger et 
al. 2013 
3 1 4 3 5 5 4 4 29 (73) 
Barbato et al. 
2013 
4 5 3 2 1 4 5 5 29  (73) 
Bartholomeus
z et al. 2014 
5 5 5 2 5 4 5 5 36 (90) 
Clayson et al. 
2019 
5 5 3 2 3 5 5 5 33 (83) 
Cotter et al. 
2017 
5 5 4 3 4 5 4 5 36 (90) 
DeVylder et 
al 2013 
4 3 3 2 3 4 3 4 26 (65) 
Glenthoj et al. 
2018 
5 5 5 3 4 5 5 5 37 (93) 
Glenthoj et al. 
2016 
4 5 3 3 2 4 3 4 28 (70) 
Haining et al. 
2019 
4 4 4 4 4 2 5 5 32 (80) 
Ohmuro et al. 
2016 
5 5 5 4 4 5 5 5 38 (95) 
Stanford et al. 
2011 
5 4 5 4 4 5 5 5 37 (93) 
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Appendix 1.5 Description of Functioning Measures in Included Studies 
 
Measure Name Domains Included/Measure Description 
 
Community Functioning: Observer or Informant Rating 
Social and Occupational 
Functioning Assessment 
Scale 1 
Global rating of functioning scored from 0-
100 
Global Assessment of 
Functioning 2 
Global rating of functioning including 
symptoms severity– single score from 0-100 
Global Functioning Scale 
– Social3 
Engagement in social activity and 
interpersonal relationships  
Global Functioning Scale 
– Role3 
Educational and Vocational Engagement 
and performance 
Personal and Social 
Performance Scale4 
Functioning in four areas– socially useful 
activities, personal and social relationships, 
self-care tasks and disturbing and aggressive 
behaviours – rated on four anchor points to 
obtain overall rating of personal and social 
performance.  
 
Community Functioning - Self-Report Measures 
 
Social Functioning Scale 
– Self report5 
Social engagement, interpersonal 
communication, independence performance, 
independence competence, recreation, 
prosocial, employment 
Social Responsiveness 
Scale6 
Total score representing overall social 
deficits and 5 sub-scores: Social Awareness 
Social Cognition, Social Communication, 
Social Motivation, Restricted Interests and 
Repetitive Behaviour  
Assessment of Quality of 
Life7 
5 dimensions: illness, independent living, 
social relationships, physical senses and 
psychological wellbeing 
Social Adjustment Scale8 Self report of individuals satisfaction with 
social situation 
 
Social Skills Performance 
 
High Risk Social 
Challenge Task9 
Videotaped speech challenge coded for 
social functioning 
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Chapter 2 Appendices 
 
Appendix 2.1 Ethical Approval Letter  
 
 
 
 
East of Scotland Research Ethics Service (EoSRES)  
Research Ethics Service 
Tayside medical Science Centre 
Residency Block Level 3 
George Pirie Way 
Ninewells Hospital and Medical School 
Dundee, DD1 9SY 
Professor Hamish McLeod 
Professor of Clinical Psychology 
University of Glasgow Gartnavel 
Royal Hospital Administration 
Building 1055 Great western 
Road G12 0HX 
Date: 26 February 2019 
Your Ref: 
Our Ref: LR/19/ES/0006 
Enquiries to: Mrs Lorraine Reilly 
Direct Line: 01382 383878 
Email: eosres.tayside@nhs.net 
 
Dear Professor McLeod 
Study Title: The relationship between social cognition, negative 
symptoms and interpersonal functioning 
in persistent psychosis 
REC reference: 19/ES/0006 
Protocol number: N/A 
IRAS project ID: 248610 
Thank you for your letter dated 19 February 2019, responding to the 
Committee’s request for further information on the above research and 
submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chair. 
We plan to publish your research summary wording for the above study on the 
HRA website, together with your contact details. Publication will be no earlier 
than three months from the date of this opinion letter. Should you wish to provide 
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a substitute contact point, require further information, or wish to make a request to 
postpone publication, please contact hra.studyregistration@nhs.net outlining the 
reasons for your request. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion 
for the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below. 
Conditions of the favourable opinion 
The REC favourable opinion is subject to the following conditions being met prior 
to the start of the study. 
Management permission must be obtained from each host organisation prior to 
the start of the study at the site concerned.  
Management permission should be sought from all NHS organisations involved in the 
study in accordance with NHS research governance arrangements. Each NHS 
organisation must confirm through the signing of agreements and/or other documents that 
it has given permission for the research to proceed (except where explicitly specified 
otherwise). 
Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS 
permission for research is available in the Integrated Research Application System, at 
www.hra.nhs.uk or at http://www.rdforum.nhs.uk. 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance 
should be sought from the R&D office on the information it requires to give permission 
for this activity. 
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation. 
Sponsors are not required to notify the Committee of management permissions from 
host organisations 
Registration of Clinical Trials 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees). 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as 
part of the annual progress reporting process. 
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory. 
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials 
will be registered, however, in exceptional circumstances non registration may be 
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permissible with prior agreement from the HRA. Guidance on where to register is provided 
on the HRA website. 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
Ethical Review of Research Sites  
NHS Sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see "Conditions of the favourable opinion" below). 
Non-NHS sites 
The Committee has not yet completed any site-specific assessment (SSA) for the non-
NHS research site(s) taking part in this study. The favourable opinion does not therefore 
apply to any non-NHS site at present. We will write to you again as soon as an SSA 
application(s) has been reviewed. In the meantime no study procedures should be initiated 
at non-NHS sites.
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Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Version Date 
Copies of advertisement materials for research participants 
[Staff Information sheet] 
1.04 14 February 
2019 
Covering letter on headed paper [Covering Letter Response to 
REC Provisional Opinion] 
 19 February 
2019 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Evidence of sponsor indemnity (non-NHS)] 
 06 August 
2018 
GP/consultant information sheets or letters [Notification of 
Participation Letter] 
1.04 19 February 
2019 
IRAS Application Form [IRAS_Form_20122018]  20 December 
2018 IRAS Checklist XML [Checklist_20122018]  20 December 
2018 IRAS Checklist XML [Checklist_21022019]  21 February 
2019 Participant consent form [Consent Form] 1.04 14 February 
2019 Participant information sheet (PIS) [PIS] 1.04 14 February 
2019 Referee's report or other scientific critique report [Proposal 
feedback and Review] 
 19 February 
2018 
Research protocol or project proposal [Study Protocol] 1.04 19 February 
2019 Sample diary card/patient card [Case Record Form] 1.04 14 February 
2019 Summary CV for Chief Investigator (CI) [Hamish McLeod CI 
CV] 
 09 August 
2018 
Summary CV for student [Anna Kondol CV]   
Validated questionnaire [ACIPS]   
Validated questionnaire [CAINS] 1.0 03 May 2012 
Validated questionnaire [DASS-21]   
Validated questionnaire [Hinting Task]   
Validated questionnaire [PSP See Table 1]   
Validated questionnaire [TEPS]   
Validated questionnaire [UCLA Loneliness Scale] 3  
Validated questionnaire [Phonemic Fluency] 1.01 30 November 
2018 Validated questionnaire [Trail Making Test Part B] 1.01 30 November 
2018 Validated questionnaire [BLERT]   
 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK. 
After Ethical Review 
Reporting Requirements 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable 
opinion, including: 
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 Notifying substantial amendments 
Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
The HRA website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures. 
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the 
feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-
hra/governance/qualityassurance/  
HRA Training 
We are pleased to welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/ 
19/ES/0006 Please quote this number on all correspondence 
With the Committee’s best wishes for the success of this 
project. Yours sincerely 
 
pp. 
Dr Robert Rea 
Chair 
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Appendix 2.2 NHS Greater Glasgow and Clyde Research and Design Study 
Approval 
 
 
Administrator: Mrs Elaine O’Neill R&D 
Management Office 
Telephone Number: 0141 232 1815 West 
Glasgow ACH 
E-Mail: elaine.o’neill2@ggc.scot.nhs.uk Dalnair 
Street 
Website: www.nhsggc.org.uk/r&d
 Glasgo
w G3 8SW 
4 April 2019 
 NHS GG&C Board Approval 
Dear Dr I Kevan, 
Study Title: The Relationship between Social Cognition, Negative 
Symptoms and Interpersonal Functioning in Persistent 
Psychosis  
Principal Investigator: Dr Ian Mark Kevan 
GG&C HB site Gartnavel Royal Hospital 
Sponsor NHS Greater Glasgow and Clyde 
R&D reference: GN18MH640 
REC reference: 19/ES/0006 
Protocol no: V1.04; 19/02/2019 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now 
able to grant Approval for the above study. 
Conditions of Approval 
1. For Clinical Trials as defined by the Medicines for Human Use Clinical 
Trial Regulations, 2004 
a. During the life span of the study GGHB requires the following 
information relating to this site 
i. Notification of any potential serious breaches. 
ii. Notification of any regulatory inspections. 
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It is your responsibility to ensure that all staff involved in the study at this site 
have the appropriate GCP training according to the GGHB GCP policy 
(www.nhsggc.org.uk/content/default.asp?page=s1411), evidence of such 
training to be filed in the site file. 
2. For all studies the following information is required during their lifespan. 
a. Recruitment Numbers on a monthly basis 
b. Any change of staff named on the original SSI form 
c. Any amendments – Substantial or Non Substantial 
d. Notification of Trial/study end including final recruitment figures 
e. Final Report & Copies of Publications/Abstracts 
Please add this approval to your study file as this letter may be subject to 
audit and monitoring. Your personal information will be held on a secure 
national web-based NHS database. I wish you every success with this research 
study 
Yours sincerely, 
 
Mrs Elaine O’Neill 
Senior Research Administrator 
Cc: Emma Jane Gault (GU) 
 
 
 
 
 
 
 
 
 
 
 
87 
 
Appendix 2.3 Participant Information Sheet 
 
 
 
 
Participant Information Sheet 
Study Title: Understanding Interpersonal Functioning in Persistent Psychosis 
 
Invitation and Brief Summary 
We would like to invite you to take part in a research study. Before you decide, we would 
like you to understand why the research is being done and what it would involve for you. 
We will go through the information sheet with you and answer and questions you have 
before you decide whether you want to take part.  
 
Why are we doing this research? 
Research has shown that people with long term psychosis often have ongoing problems 
with their day to day functioning, including how they get on with others. This can happen 
even when some of their other symptoms have improved. We know that the ability to work 
out what other people are thinking and feeling (social cognition) can affect recovery of 
functioning. Recovery of functioning is also affected by “negative symptoms” such as loss 
of motivation. We are conducting our research to help us understand how difficulties with 
social cognition (the ability to understanding how other people think and feel) and negative 
symptoms (lack of motivation and loss of interest)  might lead people to have difficulties in 
how they get on with other people (i.e. their interpersonal functioning). We hope that 
finding out more about how these different factors are related will help us to develop more 
effective psychological therapies. 
 
Why have I been invited to take part? 
You are being invited to take part because we are recruiting people aged between 18 and 65 
who have experienced psychosis and are admitted to the long -term rehabilitation wards of 
NHS Greater Glasgow and Clyde. We are hoping to recruit 40 people to take part.  
 
Do I need to take part? 
No, participation is entirely voluntary. It is up to you if you want to take part. One of the 
research team will go through the information sheet and the study in more detail with you. 
If you decide to take part, you will be asked to sign a consent form. You are free to 
withdraw from the study at any time, without giving a reason. Choosing to participate or 
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not  will not affect your usual care and treatment now or in the future. If you decide to 
withdraw from the study at any point, we will keep any test data that we have already 
collected and may use this in our analysis. However, we will not collect any further data 
either from yourself, your records or your clinical team.   
 
What will happen to me if I take part? 
If you give consent to take part, you will be asked to attend a single session with the 
researcher. This will take place on the ward and will last between 90 minutes and two hours 
with time for breaks where needed. This will be arranged so that it does not interfere with 
any of your meal or recreation times. The test session will be administered by the 
researcher but you will have the option of having a member of ward staff who you know 
well, such as a key worker, accompany you.  
 
The testing session will involve: 
• An interview asking about your symptoms. With your consent we will voice record this to 
use for scoring the interview. If you do not wish to have this recorded you can still take part 
and we will write down your answers instead. 
• Questionnaires asking about your mood, levels of motivation and loneliness. 
• Tasks of social cognition – this will include watching a video and identifying emotions and 
listening to some short stories and answering some questions 
• Tasks of cognition – this will include a paper and pencil task connecting letters and numbers, 
and a task coming up with lists of words.  
 
We will also ask to speak to a member of your clinical team to get a rating of your recent 
levels of interpersonal functioning on the ward. 
 
As part of the study we would also request permission to look at your medical notes to 
gather some demographic information such as your age, medication, diagnosis and the date 
of your admission to the ward. 
 
This study does not involve any change to your normal care. We will not prescribe or 
change any medication, collect any blood samples or ask you to do anything differently 
other than what we ask you to complete during the one-off testing session. 
 
We will write to your Psychiatrist to let them know you are taking part in the study. 
 
What are the possible benefits of taking part? 
There are no direct benefits to taking part in this study.  However, this research may help 
improve our understanding of the factors that affect personal recovery and we will use this 
information to develop more effective treatments.  
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What are the possible disadvantages or risks of taking part? 
There are no significant risks associated with taking part in this research although that it is 
possible that a small number of people could find some of the questions upsetting. You 
may also find that the testing session is quite tiring. We will check how you are feeling 
regularly throughout the testing session and you can let us know if you are feeling upset or 
want to take a break. We will pause testing and support you with any distress you are 
experiencing. If you or the researcher feel that you are too distressed to continue or that it 
would be harmful to continue then we will stop the testing session and inform a member of 
your clinical team who will offer you support. You will be able to take breaks during the 
test session to minimise fatigue as required.  
 
Will my results be shared with anyone? 
With your consent, we will give a copy of your results to your clinical team to help them 
understand you and plan care. This information will be securely stored in your medical 
records and will not be kept by the research team.  
 
Will my information in the study be kept confidential? 
Yes – we will follow ethical and legal practices to keep your data safe and confidential. 
Other than sharing your results with your clinical team (if you consent), all data will be 
anonymous and stored securely on University of Glasgow computers and secure locked 
filing cabinets on NHS Greater Glasgow and Clyde premises. This data will only be 
accessed by members of the research team and possibly the study Sponsor, NHS GG&C, to 
check that the study is being carried out properly. Anonymised data will be stored for 10 
years after the study finishes before being securely destroyed. The voice recording of the 
clinical interview will be stored securely on NHS GG&C computers until the end of the 
study. This will be used to score a clinical interview which will be anonymised and stored 
on University of Glasgow computers  
 
What will happen with the results? 
The study is being carried out as part of Anna Kondol’s Doctorate in Clinical Psychology 
training. This means that the results will be written up and submitted to the university in the 
form of a thesis. The research will also be examined through an oral examination. We hope 
to publish the results in an academic journal afterwards. A summary of the results will be 
circulated to the wards which took part in the research. Your data and information will not 
be identifiable from any of the published results of the study. If you would like to receive a 
copy of the results, the research team will make this available to you after the study has 
finished.  
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Who has reviewed this study? 
The East of Scotland Research Ethics Service REC 1, which has responsibility for 
scrutinising all proposals for medical research on humans, has examined the proposal and 
has raised no objections from the point of view of research ethics. It is a requirement that 
your records in this research, together with any relevant medical records, be made available 
for scrutiny by monitors from NHS Greater Glasgow and Clyde whose role is to check that 
research is properly conducted and the interests of those taking part are adequately 
protected.  NHS Greater Glasgow and Clyde Research and Development Department have 
also reviewed this study and given it approval to proceed.  
Further information and contact details  
If you wish to find out more about this study and your participation, please contact Anna 
Kondol on 0141 211 0607 or a.lamont.1@research.gla.ac.uk.  
 
If you would like to speak with someone independent who is not involved in the study, you 
can contact Professor Tom McMillan on 01412110354 or 
Thomas.McMillan@glasgow.ac.uk 
 
What if I want to make a complaint? 
If you wish to make a complaint about this study you can 
 
 Write to us: 
Complaints Department 
West Glasgow Ambulatory Care Hospital 
Dalnair Street 
Glasgow 
G3 8SJ 
Phone us: 0141 201 4500 
Email us: complaints@ggc.scot.nhs.uk 
 
 
How we will use your data 
NHS Greater Glasgow and Clyde is the sponsor for this study based in the United 
Kingdom. We will be using information from you and your medical records in order to 
undertake this study and will act as the data controller for this study. This means that we 
are responsible for monitoring that your information is being collected, used, and stored 
properly. NHS Greater Glasgow and Clyde may conduct audits of the research to ensure 
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quality and governance procedures are adhered to. Information about this study and its 
conduct may be kept by the study sponsor for up to 10 years after the study has finished.  
 
Your rights to access, change or move your information is limited, as we need to manage 
your information in specific ways in order for the research to be reliable and accurate. If 
you withdraw from the study, we will keep the information about you that we have already 
obtained. To safeguard your rights, we will use the minimum personally-identifiable 
information possible. 
 
You can find out more about how we use your information here 
https://www.nhsinform.scot/care-support-and-rights/health-rights/confidentiality-and-data-
protection/how-the-nhs-handles-your-personal-health-information .  
 
Thank you for reading this Information Sheet. 
 
 
 
Matriculation Number: 2292988l 
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Appendix 2.4 Major Research Project Proposal  
 
 
Name of Assessment: MRP Proposal 
 
Title of Project:  The relationship between social cognition, negative symptoms 
and interpersonal functioning in persistent psychosis 
 
Matriculation Number:  2292988l 
 
Academic Supervisor: Hamish McLeod 
 
Field Supervisor: Ian Mark Kevan 
  
Submission Date: 21-5-18 
 
Version Number: 7 
 
Word Count: 3582 
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Abstract 
 
Background: Schizophrenia is associated with significant disruption to interpersonal 
functioning. There has been an increasing interest in describing and understanding the 
factors which might contribute to an individual’s everyday functioning. Neurocognition 
and social cognition have been identified as important predictors of functioning, with 
social cognition posited as more predictive of real world behaviour that neurocognition. 
The pathway from social cognition to interpersonal functioning remains to be tested 
and described to identify key areas for treatment. Negative symptoms are another 
important predictor of functioning and may mediate the relationship between social 
cognition and interpersonal functioning.  
Aims: The aim of the current study is to explore the relationship between social 
cognition, negative symptoms and interpersonal functioning. We aim to explore 
whether social cognition and negative symptoms are correlated, and whether negative 
symptoms mediate the relationship between social cognition and interpersonal 
functioning. In addition, we aim to test a predictive model of interpersonal functioning 
which hypothesises that difficulty processing rapidly unfolding real-world information, 
difficulties in identifying and interpreting social cues, and feelings of apathy and 
amotivation lead to poorer interpersonal functioning and potentially loneliness.   
Method: The present study will recruit patients with schizophrenic-spectrum illnesses 
from NHS Greater Glasgow and Clyde Rehabilitation Wards. Using a cross-sectional 
design, participants will complete a battery of measures including measures of social 
cognition, neurocognition, negative symptoms and measures of interpersonal 
functioning and loneliness.  
Applications: This study has applications in better understanding potential pathways to 
poor interpersonal functioning in patients with chronic schizophrenia-spectrum 
conditions.  By identifying the early links in the pathway from basic neuro/social 
cognitive deficits to poor functioning, this will allow us to identify specific targets for 
remediation.  
 
 
 
Introduction 
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Schizophrenia is one of the leading causes of disability globally (Whiteford et al., 
2013). A core feature of schizophrenia is functional deficits, such as deficits in 
social and occupational functioning. In spite of advances in antipsychotic 
treatments and the availability of medications which are somewhat effective in 
treating positive symptoms such as delusions and hallucinations (Leucht et al., 
2012) patients continue to experience significant difficulty in their daily lives 
(Brissos et al., 2011). Identifying those factors which may underlie poor 
psychosocial functioning in schizophrenia and developing targeted treatments has 
become a major focus for researchers (Juckel and Morosini, 2008).  
 
Psychosocial functioning in schizophrenia 
A decline in psychosocial functioning in a core feature of schizophrenia (Brissos et 
al., 2011) Ro and Clark (2009) define psychosocial functioning as an “individuals’ 
performance in their environment regarding significant aspects of daily living”. 
Many people diagnosed with schizophrenia experience impairments in social 
interactions, maintaining relationships and workplace performance (Brissos et al., 
2011) which have a deleterious effect on their overall recovery. Operationalisation 
of psychosocial functioning varies but has generally focussed on activities of daily 
living and self-care, fulfilment of work requirements, engagement in meaningful 
activity etc. One aspect of psychosocial functioning which is of interest is 
interpersonal functioning – e.g. the ability to develop and maintain relationships. 
Interpersonal functioning may be particularly important to an individual’s outcome 
in schizophrenia as it may influence other types of functioning through increased 
social capital (Fett et al., 2011). Indeed research suggests social connectedness is a 
strong predictor of overall health in the general population (Fiorillo and Sabatini, 
2011). Most studies looking at functioning in schizophrenia have focussed on 
broader measures of psychosocial functioning. Interpersonal functioning is a 
potentially important treatment target to improve the long-term outcome for 
schizophrenic patients. 
  
Predictors and correlates of psychosocial functioning 
There has been a surge in research exploring what may underlie poor psychosocial 
functioning in schizophrenia. A review conducted by Green (1996) highlighted the 
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importance of neurocognitive deficit. The review included 16 studies which looked 
at the relationship between various domains of neurocognition and community 
functioning. They concluded that patients with cognitive deficits, e.g. verbal 
memory, had poorer community functioning. A further systematic review of 37 
studies found correlations between cognition and functioning ranging between 0.2 
and 0.6 (Green et al., 2000). Theoretically if an individual is cognitively 
compromised this could affect their ability to learn, problem solve and to carry out 
important tasks in an efficient manner. Understanding this relationship has been 
important for re-thinking treatment targets in schizophrenia, beyond positive 
symptoms.  
 
However, neurocognition only accounts for between 20-60% of variance and 
cognitive remediation programmes suggest that improving cognitive functioning 
alone does not necessarily lead to improved overall functioning (Wykes et al., 
2011). Clearly, there are other factors which are important for understanding 
psychosocial functioning, such as social cognition.  
 
Social cognition is defined as “the ability to construct representations of the relation 
between oneself and others and to use those representations flexibly to guide social 
behaviour’’ (Adolphs, 2001). Social cognitive abilites consist of various domains of 
functioining - 1) Theory of mind 2) emotion perception 3) Social perception and 
knowledge and 4) attribution style (Fett et al., 2011). Social congnition is 
theoretically important for social interactions as our ability to identify and interpret 
how others are thinking and feeling and to apply that knowledge to a particular 
situation determines how we perform in interpersonal situations.  
 
A review by  Couture et al. (2006) of  22 studies found small to modest effect sizes 
between emotion perception, theory of mind and social perception, and functional 
outcome such as community functioning, social behaviour, social skills and 
problem solving. Fett et al., (2011) conducted a meta-analysis of 21 studies and 
found associations between theory of mind, emotion perception and social skills 
and functional outcome with effect sizes ranging between 0.22 and 0.48. Though 
there is overlap between cognitive and social cognitive abilities, social cognition 
has been found to be a seperable domain in schizophrenia (Sergi et al., 2007), may 
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mediate the relationship between neurocognition and community functioning 
(Schmidt et al., 2011) and may account for more variance in functioning than 
neurocognition (Fett et al., 2011). 
 
There remain unresolved issues regarding the relationship between social cognition 
and other important correlates of functional outcome such as negative symptoms 
which warrant further exploration. Negative symptoms in schizophrenia are 
generally understood as falling into two broad constructs – ‘expressive’  
encompassing blunted affect and alogia, and ‘experiential’ including anhedonia, 
asociality and apathy (Marder and Galderisi, 2017). Negative symptoms, and in 
particular experiential symptoms, are associated with poorer functional outcome. 
Lysaker et al. (2004) found that fewer negative symptoms was associated with 
better global functioning, while Ventura et al. (2009) in a meta-analysis of 73 
studies found that negative symptoms correlated significantly with functioning (r=-
.42). Other studies have suggested that apathy and motivation may account for 
between 18 and 75% of variance in global functioning (Foussias et al., 2011, Chang 
et al., 2016)  
 
It has also been suggested that experiential negative symptoms mediate the 
relationship between neurocognitive deficits and outcome. Using statistical 
modelling Thomas et al. (2017) tested a bottom-up model by which neurocognitive 
deficits contribute to social cognitive deficits and negative symptoms and 
subsequently functioning and found this to be the best fit for the data. Similar 
models have been supported by previous research (Green et al., 2012), and in 
studies examining individuals at ‘ultra-high risk’ of schizophrenia (Glenthoj et al., 
2017).  
 
What has been less fully explored is whether there is a potential pathway from 
social cognition to negative symptoms to interpersonal functioning. There is 
evidence that negative symptoms are associated with social cognition, for example 
Hofer et al. (2009) found that poor affect recognition was associated with worse 
negative symptoms and some studies have found evidence that negative symptoms 
may mediate the relationship between social cognition and functional outcome in a 
similar way as with neurocognition (Mehta et al., 2014, Lin et al., 2013, Ventura et 
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al., 2009). Some authors have suggested that the lack of distinction in the literature 
between experiential and expressive negative symptoms in the literature may 
contribute to the lack of clarity regarding the relationship between social cognition 
and negative symptoms. It may be that examining negative symptoms as two 
distinct constructs may add greater clarity.  
 
A greater understanding of the relationships between a person’s ability to 
understand social cues and rules, and their level of symptoms such as apathy and 
anhedonia and in particular whether there is a pathway from social cognition 
through negative symptoms to functioning would aid in the development of more 
targeted and specific treatment interventions to social cognitive deficits. For 
example, social cognitive deficits may lead individuals to find social tasks more 
difficult which may lead to apathy and lack of pleasure for social situations. This in 
turn could lead to a lack of engagement with others either through active or passive 
avoidance and poor interpersonal functioning. Untangling the relationship between 
these various factors will help to identify key treatment targets for remediation.  
 
Aims and Hypothesis 
 
The present study aims to examine the relationship between social cognition, 
experiential and expressive negative symptoms and interpersonal functioning. We 
hypothesise the following.   
 
1. Social cognitive deficits will be positively correlated with poorer interpersonal 
functioning 
2. Greater experiential negative symptoms will be correlated with poorer 
interpersonal functioning  
3. Social cognitive deficits will be positively correlated with greater experiential 
negative symptoms  
4. Experiential negative symptoms will mediate the relationship between social 
cognition and interpersonal functioning.  
 
In addition to these specific hypotheses, we aim to explore the relative contributions 
of executive functioning, social cognition and negative symptoms to interpersonal 
functioning. We will construct and test a regression model to determine whether 
these variables significantly predict interpersonal functioning.  
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Plan of Investigation 
 
Participants 
In patients with schizophrenia-spectrum illness within NHS Greater Glasgow and 
Clyde Rehabilitation wards.  
 
Criteria  
Inclusion 
• Diagnosis of Schizophrenia or schizoaffective disorder 
• Age 18-65 
• Stable medication (no changes in medication type or dose in 4 weeks) 
• Able to provide informed consent 
Exclusion 
• History of head injury or neurological disorder 
•  Other Axis-1 diagnosis 
• Current diagnosis of substance abuse disorder 
• IQ <85 
• Acute psychosis 
 
Recruitment Procedures  
Participants who may be suitable for the study will be identified by a relevant 
clinician working within the rehabilitation wards who will provide the patient with 
written and verbal information. The participant will meet with the primary 
researcher who will provide further information and obtain informed consent.  
 
Measures  
 
Demographics 
• Length of illness  
• Medication  
• Age  
• Sex 
 
Psychopathology 
• Depression and Anxiety Stress Scale – 2nd Edition (DASS-21) (Lovibond 
and Lovibond, 1995) 
• Clinical Assessment Interview of Negative Symptoms (Kring et al., 2013) 
 
Executive Functioning 
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• Phonemic Fluency from the Verbal Fluency Test (Benton and Hamsher, 
1978) 
• Trail Making Test Part B 
 
Social Cognition  
Psychometric measures and domains of social cognition have been selected based 
on a consensus expert panel (Pinkham et al., 2013).  
 
• Emotion recognition – Bell Lysaker Emotion Recognition Task (Bryson et 
al., 1997) 
• Theory of Mind –The Hinting Task (Frith and Corcoran, 1996) 
 
Interpersonal Functioning  
• Personal and Social Performance Scale (Morosini et al., 2000) 
• Revised UCLA Loneliness Scale (Russell et al., 1980) 
 
Negative symptoms 
• The Temporal Experience of Pleasure Scale (Gard et al., 2006) 
• Anticipatory and Consummatory Interpersonal Pleasure Scale (Gooding and 
Pflum, 2014) 
 
Design 
This study will use a cross-sectional design to allow for correlational and regression 
analysis between variables.    
 
Research Procedures  
Once participants have been identified and informed consent obtained, a further 
appointment will be scheduled to administer the test battery. Test sessions will be 
conducted in a private clinic room at the NHS Hospital where they are in-patients. 
Testing sessions will be conducted by the primary researcher (AK). Testing will be 
completed in one session lasting approximately 1 hours 20 minutes plus breaks 
where necessary to minimise fatigue. The PSP will be completed by a clinician who 
knows the patient well. See Table 1 below for details of measure administration. 
Interviews will be recorded to allow for validation of the reliability of ratings on 
semi-structured interviews.  
 
Data Analysis  
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First order correlations will be performed between variables of social cognition, 
negative symptoms and interpersonal functioning/loneliness. A mediation analysis 
will be carried out to determine whether negative symptoms mediate the 
relationship between social cognition and interpersonal functioning. This will be 
conducted using the techniques outlined by Shrout and Bolger (2002). Finally, a 
multiple regression model will be used to examine the predictive validity of 
executive functioning, social cognition and negative symptoms on interpersonal 
functioning.   
 
Justification of sample size  
 
On the basis of previous studies (Fett et al., 2011, Ventura et al., 2009) we expect to 
find medium to large effect sizes for correlational analysis between social cognition 
and interpersonal functioning (r=0.48) and negative symptoms and interpersonal 
functioning (r=0.42). In addition, several studies (Konstantakopoulos et al., 2011, 
Rocca et al., 2014) have found large effect sizes for a multivariate regression model 
similar to that proposed by the present study (r2=0.75 and r2=0.54 respectively).  As 
such we expect to find large effect sizes across our analyses. Based on a 
multivariate regression model with 3 predictors and large effect size would require 
a sample size of 40 participants. This is in keeping with sample sizes used in similar 
studies.  
 
Settings and Equipment 
Rehabilitation wards of Glasgow City - Parkhead Hospital, Leverndale, Stobhill 
and Gartnavel Royal. Equipment will consist of the specified measures which are 
administered on a laptop or paper and pencil, and a voice recorder. 
 
Table 4: Study Measures and Administration Times 
Method 
Measure 
Name 
Domain 
Admin 
Time 
Description 
Clinician 
Administered 
CAINS Psychopathology 35 
Semi structured 
interview 
Hinting 
Task 
Social cognition 6 
10 vignettes and 
questions 
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BLERT Social cognition 10 
21 10-second video 
clips. Participant 
identifies emotion 
Verbal 
Fluency 
Executive 
Functioning 
5 
3 letters, participant 
has 1 minute to 
generate words 
Trails 
(Part B) 
Executive 
Functioning 
5 
Paper and pencil task 
connecting letters 
and numbers. Total 
completion time 
recorded. 
Discontinue after 
300 seconds 
Self-rated 
DASS-21 
Psychopatho
logy 
5 
21-item 
questionnaire 
UCLA 
Loneliness 
Interpersonal 
functioning 
5 
20-item 
questionnaire 
TEPS 
Negative 
Symptoms 
5 
20-item 
questionnaire 
ACIPS 
Negative 
symptoms 
5 
17-item 
questionnaire 
Clinician 
Rated 
PSP 
Interpersonal 
functioning 
Clinician 
rated 
 
Total 
Participant 
Time 
81 minutes (1 hour 21 minutes) 
 
Health and Safety Issues  
 
The proposed study will be undertaken on various hospital sites across NHS 
Greater Glasgow and Clyde and as such relevant local Health and Safety policies 
and procedures will be adhered to. 
 
Researcher Safety Issues  
Participants with a diagnosis of schizophrenia will be recruited which presents a 
potential risk to the researcher. A psychiatrist will be asked to comment on their 
ability to give informed consent and suitability to participate in the study. 
Participants in the acute period of psychosis will not be recruited to the study. The 
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primary researcher will carry an alarm throughout interviews. The research will be 
conducted on hospital sites across NHS Greater Glasgow and Clyde and all relevant 
health and safety policies and procedures will be adhered to. All interviews will be 
conducted during working hours and a member of staff will be aware of the 
researcher’s location and intended completion time.  
 
Participant Safety Issues  
A psychiatrist will be asked to comment on a patient’s ability to provide informed 
consent to participant in the study. Participants will be advised of their ability to 
withdraw from the study at any time. Participants may become distressed during the 
interview. The researcher will monitor participants for signs of distress through the 
interview. At any indication of distress, the researcher will use their clinical skills to 
manage this. The researcher will ask the participant if they wish to continue and 
remind them of their ability to withdraw. Any significant distress during the 
interview will be relayed to the medical team on the ward.  
 
 
Ethical Issues and approval 
 
Ethical approval 
Following approval of the research proposal by the University of Glasgow, Mental 
Health and Wellbeing Research Director ethical and management approval will be 
sought. Management approval will be sought from NHs Greater Glasgow and 
Clyde Research and Development and ethical approval will be sought from West of 
Scotland Research Ethics Service.  
 
Ethical Issues to address 
1. Participants ability to provide informed consent 
2. Participant fatigue and/or distress during testing 
 
Financial Issues  
 
A request has been submitted for funding of £54.18 to cover the cost of stationery 
and photocopying.  
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Timetable  
 
It is proposed that data collection will commence in September 2018. The 
anticipated end date for the study is April 2019.  
 
 
Practical Applications 
 
This study has applications in better understanding potential pathways to poor 
interpersonal functioning in patients with chronic schizophrenia-spectrum 
conditions.  By identifying the early links in the pathway from basic neuro/social 
cognitive deficits to poor functioning, this will allow us to identify specific targets 
for remediation.  
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